

# Rule H-2009-03 Data Filing Checklist- BCBSVT

Due Date: 7/15/2021

**1. Attestation of compliance to Part 5 of Rule H-2009-03**

**Documentation submitted:** BCBSVT Attestation of Compliance with Part 5-2021-07-15.pdf

**2. Section 6.3 Network Adequacy Reporting- 2021**

**Documentation submitted:** BCBSVT 6.3 Network Adequacy Reporting-2021-07-15.pdf

**3. A detailed accreditation report from NCQA that includes VT QHP plans.**

**Documentation Submitted:**

- 2020\_Certificate\_of\_Accreditation-Commercial\_BCBSVT.pdf
- 2020\_Certificate\_of\_Accreditation-Exchange\_BCBSVT.pdf
- 2020\_Accreditation\_Results\_BCBSVT.pdf
- 2020\_Accreditation\_Results\_TVHP.pdf

**4. A list of Rx that fall in the “specialty” category that can only be acquired through the specialty vendor as of July 1, 2018.**

**Documentation submitted:** BCBSVT Specialty Drug List-Effective 2021-07-01.pdf

Blue Cross Blue Shield of Vermont Departmental Attestation of Compliance with Rule H-2009-03, Part 5:

5.1 Ensuring Adequacy of Access to Providers and Continuity of Services:

06/29/2021  
Date

*Kate McIntosh*  
Kate McIntosh (Jun 29, 2021 16:03 EDT)  
Kate McIntosh  
Senior Medical Director

5.2 Credentialing Verification Practices:

06/29/2021  
Date

*Lou McLaren*  
Lou McLaren (Jun 29, 2021 15:48 EDT)  
Lou McLaren  
Director, Provider Services

5.3 Provider Contracting, Fiscal Incentives and Disincentives:

06/29/2021  
Date

*Lou McLaren*  
Lou McLaren (Jun 29, 2021 15:48 EDT)  
Lou McLaren  
Director, Provider Services

I, Joshua Plavin, MD, attest to the Commissioner of the Department of Financial Regulation that Blue Cross Blue Shield of Vermont is in compliance with Part 5 of Rule H-2009-03

06/30/2021  
Date

*Joshua Plavin, MD*  
Joshua Plavin, MD (Jun 30, 2021 10:06 EDT)  
Joshua Plavin, MD  
Vice President & Chief Medical Director

**Blue Cross and Blue Shield of Vermont**  
**Rule H-2009-03, Part 6: 6.3 Network Adequacy Reporting**  
**July 15, 2021**

**A. Measurement Method**

The Plan monitors specialties that serve as PCPs by specialty and in aggregate. The Plan defines the following areas as primary care practice: pediatrics, internal medicine, family practice. For purposes of this evaluation the specialty of family practice will include general practice, naturopaths, nurse practitioners and geriatrics.

The Plan also monitors high-volume and high-impact specialties. The Plan considers obstetrics and gynecology (OB/GYN) a high-volume specialty and oncology a high-impact specialty.

In addition, we evaluate the availability of mental health and substance use disorder practitioners.

**Table 1: Availability Standards and Monitoring Methodology**

<b>Availability- Travel Time and Number of Practitioners Standards</b>	<b>Methodology</b>	<b>Frequency</b>
Primary Care Practitioners: Choice of at least two age-appropriate network PCPs, who are accepting new patients, within 30 minutes travel time	GeoAccess report of travel time	Annually
High-Volume Specialty: Choice of at least one obstetrics and gynecology practitioner within 60 minutes travel time.		
High-Impact Specialty: Choice of at least one Oncology practitioner within 60 minutes travel time		
Choice of at least one mental health/substance use disorder practitioner within 30 minutes travel time		
<b>Availability- Number of Practitioners Standard</b>	<b>Methodology</b>	<b>Frequency</b>
Primary Care Practitioners: Number of age-appropriate PCPs that are accepting new patients equals a ratio of one for every 2,000 or less members	Ratio	Annually
High Volume Specialty: Number of Obstetrics and gynecology specialists equals a ratio of one for every 2,500 or less members	Ratio	Annually
Number of psychiatrists equals a ratio of one for every 5,000 or less members	Ratio	Annually
Number of psychologists-doctoral level equals a ratio of one for every 1,500 or less members	Ratio	Annually

Availability- Travel Time and Number of Practitioners Standards	Methodology	Frequency
Number of master of social work and other master level mental health/substance use disorder practitioners equals a ratio of one for every 1,500 or less members	Ratio	Annually

**B. Results**

**Table 2: Availability Monitoring Results for 2021 and 2020\***

Availability Standards	Performance Goal	2021 Results	2020 Results
PCPs Choice of at least two age-appropriate network PCPs within 30 minutes travel time	At least 90% of the Plan's membership is within 30 minutes of two age-appropriate PCPs, and at least 80% of the Plan's membership is within 30 minutes of two age appropriate network PCPs who are accepting new patients.	<b>HMO/POS Network: 100%</b> <i>(49,038 members with adequate network availability/49,038 total members)</i>	<b>HMO/POS Network: 100%</b> <i>(49,387 members with adequate network availability/49,387 total members)</i>
		<i>Total number of network PCPs: 1845</i>	<i>Total number of network PCPs: 1625</i>
		<b>TVHP Network: 100%</b> <i>(390/390)</i>	<b>TVHP Network:100%</b> <i>(1,098/1,098)</i>
		<i>Total number of network PCPs: 1845</i>	<i>Total number of network PCPs: 1625</i>
		<b>PPO/EPO Network: 100%</b> <i>(57,746/57,746)</i>	<b>PPO/EPO Network: 100%</b> <i>(62,913/62,913)</i>
		<i>Total number of network PCPs: 1845</i>	<i>Total number of network PCPs: 1625</i>
		<b>QHP Network: 100%</b> <i>(33,053/33,053)</i>	<b>QHP Network: 100%</b> <i>(36,036/36,036)</i>
<i>Total number of network PCPs: 1845</i>	<i>Total number of network PCPs: 1625</i>		

Availability Standards	Choice of at least two age-appropriate network PCPs within 30 minutes travel time	
Performance Goal	2021 Results	2020 Results
<p align="center"><b>Pediatricians</b></p> <p>At least 90% of the Plan's membership is within 30 minutes of two age-appropriate PCPs, and at least 80% of the Plan's membership is within 30 minutes of two age appropriate network PCPs who are accepting new patients.</p>	<p><b>HMO/POS Network: 100%</b> (10,157/10,157)</p>	<p><b>HMO/POS Network: 100%</b> (10,382/10,383)</p>
	<p>Total number of network Pediatricians: 337</p>	<p>Total number of network Pediatricians: 238</p>
	<p><b>TVHP Network: 100%</b> (60/60)</p>	<p><b>TVHP Network: 100%</b> (170/170)</p>
	<p>Total number of network Pediatricians: 337</p>	<p>Total number of network Pediatricians: 238</p>
	<p><b>PPO/EPO Network: 100%</b> (12,152/12,152)</p>	<p><b>PPO/EPO Network: 99.9%</b> (13,392/13,405)</p>
	<p>Total number of network Pediatricians: 337</p>	<p>Total number of network Pediatricians: 238</p>
	<p><b>QHP Network: 100%</b> (3,799/3,799)</p>	<p><b>QHP Network: 100%</b> (4,185/4,185)</p>
<p align="center"><b>Internal Medicine</b></p> <p>At least 90% of the Plan's membership is within 30 minutes of two age-appropriate PCPs, and at least 80% of the Plan's membership is within 30 minutes of two age appropriate network PCPs who are accepting new patients.</p>	<p><b>HMO/POS Network:100%</b> (38,881/38,881)</p>	<p><b>HMO/POS Network:100%</b> (39,004/39,004)</p>
	<p>Total number of network internal medicine: 347</p>	<p>Total number of network internal medicine: 250</p>
	<p><b>TVHP Network:100%</b> (330/330)</p>	<p><b>TVHP Network:100%</b> (928/928)</p>
	<p>Total number of network internal medicine: 347</p>	<p>Total number of network internal medicine: 250</p>
	<p><b>PPO/EPO Network: 100%</b> (45,594/45,594)</p>	<p><b>PPO/EPO Network: 100%</b> (49,508/49,508)</p>
<p>Total number of network internal medicine: 347</p>	<p>Total number of network internal medicine: 250</p>	

Availability Standards	Choice of at least two age-appropriate network PCPs within 30 minutes travel time	
Performance Goal	2021 Results	2020 Results
	<b>QHP Network: 100%</b> <i>(29,254/29,254)</i>	<b>QHP Network: 100%</b> <i>(31,851/31,851)</i>
	<i>Total number of network internal medicine: 347</i>	<i>Total number of network internal medicine: 250</i>
<p data-bbox="240 888 678 1035"><b>Family and General Practice (Includes Naturopaths and Nurse Practitioners that agree to hold a patient panel)</b></p> <p data-bbox="228 1083 691 1346">At least 90% of the Plan's membership is within 30 minutes of two age-appropriate PCPs, and at least 80% of the Plan's membership is within 30 minutes of two age appropriate network PCPs who are accepting new patients.</p>	<b>HMO/POS Network: 100%</b> <i>(49,038/49,038)</i>	<b>HMO/POS Network: 100%</b> <i>(49,386/49,387)</i>
	<i>Total number of network family and general practice: 1354</i>	<i>Total number of network family and general practice: 1137</i>
	<b>TVHP Network: 100%</b> <i>(390/390)</i>	<b>TVHP Network: 100%</b> <i>(1,098/1,098)</i>
	<i>Total number of network family and general practice: 1354</i>	<i>Total number of network family and general practice: 1137</i>
	<b>PPO/EPO Network: 100%</b> <i>(57,749/57,749)</i>	<b>PPO/EPO Network: 100%</b> <i>(62,913/62,913)</i>
	<i>Total number of network Family and General Practice: 1354</i>	<i>Total number of network Family and General Practice: 1137</i>
	<b>QHP Network: 100%</b> <i>(33,053/33,053)</i>	<b>QHP Network: 100%</b> <i>(36,036/36,036)</i>
	<i>Total number of network Family and General Practice: 1354</i>	<i>Total number of network Family and General Practice: 1137</i>

\* The above data measures PCPs that are accepting new patients (open panels). To determine if a PCP is accepting new patients the Plan uses provider information available through the network management provider file.

**Table 3: Availability Monitoring Results for High-Volume and High-Impact Specialists 2021 - 2020**

<b>Availability Standards</b>	Choice of at least one network practitioner from each of the specialties selected for monitoring within 60 minutes travel time.	
<b>Performance Goal</b>	<b>2021 Results</b>	<b>2020 Results</b>
<p align="center"><b>OB/GYN</b></p> <p>90% of the Plan’s membership is within 60 minutes of at least one network OB/GYN</p>	<p><b>HMO/POS Network: 100%</b> <i>(49,038/49,038)</i></p>	<p><b>HMO/POS Network: 100%</b> <i>(49,387/49,387)</i></p>
	<p><i>Total number of network OB/GYN: 344</i></p>	<p><i>Total number of network OB/GYN: 323</i></p>
	<p><b>TVHP Network: 100%</b> <i>(390/390)</i></p>	<p><b>TVHP Network: 100%</b> <i>(1,098/1,098)</i></p>
	<p><i>Total number of network OB/GYN: 344</i></p>	<p><i>Total number of network OB/GYN: 323</i></p>
	<p><b>PPO/EPO Network: 100%</b> <i>(57,746/57,746)</i></p>	<p><b>PPO/EPO Network: 100%</b> <i>(62,913/62,913)</i></p>
	<p><i>Total number of network OB/GYN: 344</i></p>	<p><i>Total number of network OB/GYN: 323</i></p>
	<p><b>QHP Network: 100%</b> <i>(33,053/33,053)</i></p> <p><i>Total number of network OB/GYN: 344</i></p>	<p><b>QHP Network: 100%</b> <i>(36,036/36,036)</i></p> <p><i>Total number of network OB/GYN: 323</i></p>
<p align="center"><b>Oncologist</b></p> <p>90% of the Plan’s membership is within 60 minutes of at least one network Oncologist or Oncologists/Hematologists</p>	<p><b>HMO/POS Network: 100%</b> <i>(49,038/49,038)</i></p>	<p><b>HMO/POS Network: 100%</b> <i>(49,387/49,387)</i></p>
	<p><i>Total number of network Oncologists: 192</i></p>	<p><i>Total number of network Oncologists: 149</i></p>
	<p><b>TVHP Network: 100%</b> <i>(390/390)</i></p>	<p><b>TVHP Network: 100%</b> <i>(1,098/1,098)</i></p>
	<p><i>Total number of network Oncologists: 192</i></p>	<p><i>Total number of network Oncologists: 149</i></p>
	<p><b>PPO/EPO Network: 100%</b> <i>(57,746/57,746)</i></p>	<p><b>PPO/EPO Network: 100%</b> <i>(62,913/62,913)</i></p>
<p><i>Total number of network Oncologists: 192</i></p>	<p><i>Total number of network Oncologists: 149</i></p>	

Availability Standards	Choice of at least one network practitioner from each of the specialties selected for monitoring within 60 minutes travel time.	
Performance Goal	2021 Results	2020 Results
	<b>QHP Network: 100%</b> (33,053/33,053)	<b>QHP Network: 100%</b> (36,036/36,036)
	Total number of network Oncologists: 192	Total number of network Oncologists: 149

Availability Standards	Choice of at least one mental health and substance use disorder practitioner within 30 minutes travel time	
Performance Goal	2021 Results	2020 Results
<b>Psychiatrist</b>  90% of the Plan's membership with MH/SUD benefits is within 30 minutes of at least one psychiatrist	<b>HMO/POS Network: 100%</b> (48,253/48,270)	<b>HMO/POS Network: 100%</b> (48,597/48,619)
	Total number of network Psychiatrists: 533	Total number of network Psychiatrists: 494
	<b>TVHP Network: 99.7%</b> (386/387)	<b>TVHP Network: 100%</b> (1,091/1,095)
	Total number of network Psychiatrists: 533	Total number of network Psychiatrists: 494
	<b>PPO/EPO Network: 99.9%</b> (43,628/43,663)	<b>PPO/EPO Network: 99.9%</b> (48,116/48,166)
	Total number of network Psychiatrists: 533	Total number of network Psychiatrists: 494
	<b>QHP Network: 100%</b> (33,037/33,053)	<b>QHP Network: 100%</b> (36,015/36,036)
	Total number of network Psychiatrists: 533	Total number of network Psychiatrists: 494
<b>Psychologist- Doctoral Level</b>  90% of the Plan's membership with MH/SUD benefits is within 30 minutes of at least one psychologist-doctoral level	<b>HMO/POS Network: 100%</b> (48,270/48,270)	<b>HMO/POS Network: 100%</b> (48,619/48,619)
	Total number of network Psychologist-doctoral level: 774	Total number of network Psychologist-doctoral level: 727
	<b>TVHP Network: 100%</b> (387/387)	<b>TVHP Network: 100%</b> (1,095/1,095)
	Total number of network Psychologist- doctoral level: 774	Total number of network Psychologist- doctoral level: 727



	<b>PPO/EPO Network: 100%</b> (43,661/43,663)	<b>PPO/EPO Network: 100%</b> (48,166/48,166)
	Total number of network Psychologist- doctoral level: 774	Total number of network Psychologist- doctoral level: 727
	<b>QHP Network: 100%</b> (33,053/33,053)	<b>QHP Network: 100%</b> (36,036/36,036)
	Total number of network Psychologist- doctoral level: 774	Total number of network Psychologist- doctoral level: 727
<b>Master Level Clinical Social Worker and Other Master Level Practitioners</b>  90% of the Plan’s membership with MH/SUD benefits is within 30 minutes of at least one master level clinical social work or other master level practitioner	<b>HMO/POS Network: 100%</b> (48,270/48,270)	<b>HMO/POS Network: 100%</b> (48,619/48,619)
	Total number of network master level CSW or other master level practitioners: 2688	Total number of network master level CSW or other master level practitioners: 2381
	<b>TVHP Network: 100%</b> (387/387)	<b>TVHP Network: 100%</b> (1,095/1,095)
	Total number of network master level CSW or other master level practitioners: 2688	Total number of network master level CSW or other master level practitioners: 2381
	<b>PPO/EPO Network: 100%</b> (43,663/43,663)	<b>PPO/EPO Network: 100%</b> (48,166/48,166)
	Total number of network master level CSW or other master level practitioners: 2688	Total number of network master level CSW or other master level practitioners: 2381
	<b>QHP Network: 100%</b> (33,053/33,053)	<b>QHP Network: 100%</b> (36,036/36,036)
Total number of network master level CSW or other master level practitioners: 2688	Total number of network master level CSW or other master level practitioners: 2381	
<b>All Outpatient Mental Health Practitioners</b>  90% of the Plan’s membership with MH/SUD benefits is within 30 minutes of at least one outpatient mental health	<b>HMO/POS Network: 100%</b> (48,270/48,270)	<b>HMO/POS Network: 100%</b> (48,619/48,619)
	Total number of outpatient mental health practitioners:3,984	Total number of outpatient mental health practitioners:3,602
	<b>TVHP Network: 100%</b> (387/387)	<b>TVHP Network: 100%</b> (1,095/1,095)
	Total number of outpatient mental health practitioners:3,984	Total number of outpatient mental health practitioners:3,602
	<b>PPO/EPO Network: 100%</b> (43,663/43,663)	<b>PPO/EPO Network: 100%</b> (48,166/48,166)
Total number of outpatient mental health practitioners:3,984	Total number of outpatient mental health practitioners:3,602	

practitioner (aggregate of above)	<b>QHP Network: 100%</b> (33,053/33,053)	<b>QHP Network: 100%</b> (36,036/36,036)
	Total number of outpatient mental health practitioners:3,984	Total number of outpatient mental health practitioners:3,602
<b>All Outpatient Substance Use Disorder Practitioners</b>  90% of the Plan's membership with MH/SUD benefits is within 30 minutes of at least one outpatient substance use disorder practitioner	<b>HMO/POS Network: 100%</b> (48,270/48,270)	<b>HMO/POS Network: 100%</b> (48,619/48,619)
	Total number of outpatient substance use disorder practitioners:4064	Total number of outpatient substance use disorder practitioners:3577
	<b>TVHP Network: 100%</b> (387/387)	<b>TVHP Network: 100%</b> (1,095/1,095)
	Total number of outpatient substance use disorder practitioners:4064	Total number of outpatient substance use disorder practitioners:3577
	<b>PPO/EPO Network: 100%</b> (43,663/43,663)	<b>PPO/EPO Network: 100%</b> (48,166/48,166)
	Total number of outpatient substance use disorder practitioners:4064	Total number of outpatient substance use disorder practitioners:3577
	<b>QHP Network: 100%</b> (33,053/33,053)	<b>QHP Network: 100%</b> (36,036/36,036)
	Total number of outpatient substance use disorder practitioners:4064	Total number of outpatient substance use disorder practitioners:3577

**Table 4: Number of Practitioners 2021-2020**

Performance Goal	2021 Result	2020 Result
<b>PCPs- Aggregate</b> Less than 2,000 members for each age-appropriate PCP that is accepting new patients	<b>HMO/POS Network: 1:27</b> (49,038/1,845)	<b>HMO/POS Network: 1:31</b> (49,387/1,625)
	<b>TVHP Network: 1:1</b> (390/1,845)	<b>TVHP Network: 1:1</b> (1,098/1,625)
	<b>PPO/EPO Network: 1:32</b> (57,746/1,845)	<b>PPO/EPO Network: 1:39</b> (62,913/1,625)
	<b>QHP Network: 1:18</b> (33,053/1,845)	<b>QHP Network: 1:23</b> (36,036/1,625)
<b>Pediatrician</b> Less than 2,000 members for each age-appropriate PCP that is accepting new patients	<b>HMO/POS Network: 1:31</b> (10,157/337)	<b>HMO/POS Network: 1:44</b> (10,383/238)
	<b>TVHP Network: 1:1</b> (60/337)	<b>TVHP Network: 1:1</b> (170/238)

	<b>PPO/EPO Network: 1:37</b> (12,152/337)	<b>PPO/EPO Network: 1:57</b> (13,405/238)
	<b>QHP Network: 1:12</b> (3,799/337)	<b>QHP Network: 1:18</b> (4,185/238)
<b>Internal Medicine</b> Less than 2,000 members for each age-appropriate PCP that is accepting new patients	<b>HMO/POS Network: 1:113</b> (38,881/347)	<b>HMO/POS Network: 1:157</b> (39,004/250)
	<b>TVHP Network: 1:1</b> (330/347)	<b>TVHP Network: 1:4</b> (928/250)
	<b>PPO/EPO Network: 1:132</b> (45,594/347)	<b>PPO/EPO Network: 1:199</b> (49,508/250)
	<b>QHP Network: 1:85</b> (29,254/347)	<b>QHP Network: 1:128</b> (31,851/250)
<b>Family and General Practice (Includes Naturopaths and Nurse Practitioners that agree to hold a patient panel)</b> Less than 2,000 members for each age-appropriate PCP that is accepting new patients	<b>HMO/POS Network: 1:37</b> (49,038/1,354)	<b>HMO/POS Network: 1:44</b> (49,387/1,137)
	<b>TVHP Network: 1:1</b> (390/1,354)	<b>TVHP Network: 1:1</b> (1,098/1,137)
	<b>PPO/EPO Network: 1:43</b> (57,746/1,354)	<b>PPO/EPO Network: 1:56</b> (62,913/1,137)
	<b>QHP Network: 1:25</b> (33,053/1,354)	<b>QHP Network: 1:32</b> (36,036/1,137)
<b>OB/GYN</b> Less than 2,500 members for each high volume specialty selected	<b>HMO/POS Network: 1:143</b> (49,038/344)	<b>HMO/POS Network: 1:153</b> (49,387/323)
	<b>TVHP Network: 1:2</b> (390/344)	<b>TVHP Network: 1:4</b> (1,098/323)
	<b>PPO/EPO Network: 1:168</b> (57,746/344)	<b>PPO/EPO Network: 1:195</b> (62,913/323)
	<b>QHP Network: 1:97</b> (33,053/344)	<b>QHP Network: 1:112</b> (36,036/323)
<b>Psychiatrist</b> Less than 5,000 members with MH/SUD benefits for each network psychiatrist	<b>HMO/POS Network: 1:91</b> (48,270/533)	<b>HMO/POS Network: 1:99</b> (48,619/494)
	<b>TVHP Network: 1:1</b> (387/533)	<b>TVHP Network: 1:3</b> (1,095/494)
	<b>PPO/EPO Network: 1:82</b> (43,663/533)	<b>PPO/EPO Network: 1:98</b> (48,166/494)
	<b>QHP Network: 1:63</b> (33,053/533)	<b>QHP Network: 1:73</b> (36,036/494)
<b>Psychologist- Doctoral Level</b> Less than 1,500 members with MH/SUD for each network psychologist- doctoral level	<b>HMO/POS Network: 1:63</b> (48,270/774)	<b>HMO/POS Network: 1:67</b> (48,619/727)
	<b>TVHP Network: 1:1</b> (387/774)	<b>TVHP Network: 1:2</b> (1,095/727)
	<b>PPO/EPO Network: 1:57</b> (43,663/774)	<b>PPO/EPO Network: 1:67</b> (48,166/727)

	<b>QHP Network: 1:43</b> (33,053/774)	<b>QHP Network: 1:50</b> (36,036/727)
<b>All Master Level Practitioners</b> Less than 1,500 members with MH/SUD benefits for each network master of social work or other master level behavioral health practitioner	<b>HMO/POS Network: 1:21</b> (48,270/2,688)	<b>HMO/POS Network: 1:21</b> (48,619/2,381)
	<b>TVHP Network: 1:1</b> (387/2,688)	<b>TVHP Network: 1:1</b> (1,095/2,381)
	<b>PPO/EPO Network: 1:21</b> (43,663/2,688)	<b>PPO/EPO Network: 1:21</b> (48,166/2,381)
	<b>QHP Network: 1:16</b> (33,053/2,688)	<b>QHP Network: 1:16</b> (36,036/2,381)

### C. Analysis

#### a. Performance Against Goal

In 2021, the Plan met all of the practitioner availability goals for all four products. The number of network practitioners reported for 2021 generally increased, in some cases significantly, for PCPs and specialties compared to this same reporting period in 2020. This is likely due to the implementation of a new operating system (NASCO) and the resulting changes in the way specialties and open panels are identified and reported. While these data changes may make trending inappropriate, the 2020 results are included in this report to show that despite the data changes overall compliance with standards and goals continues.

Please note that the performance measurement for PCPs are based on practitioners that are accepting new patients (open panel). To determine if a PCP is accepting new patients the Plan uses provider information available through the network management provider data.

#### b. Quantitative Analysis

All eleven travel time goals were met for all four products with rates between 99.7 and 100 percent compliance. The plan measured travel time for PCPs, with a breakout for specialties that serve as PCPs, as well as a high-volume specialist and a high-impact specialist. In addition, the Plans measured travel time for the following mental health and substance abuse practitioners: psychiatrist, psychologist- doctoral level, and master level MH/SUD practitioners.

The results for psychiatrists identified over ninety-nine per cent (99.7) of the PPO/EPO members were within the travel time standards. The evaluation found that Essex and Franklin Counties were the only counties with less than full compliance at eighty-eight and ninety-nine per cent compliance, respectively. All other counties were in full compliance.

The number of network practitioners as a ratio of members met all performance goals for HMO/POS, PPO/EPO, TVHP and QHP.

#### c. Qualitative Analysis

The networks are adequate based on the geographic distribution of the network practitioners as compared to the standards and performance goals. Furthermore, a very high percentage of

providers in the state contract with the Plan's networks. BCBSVT does not restrict the number of providers within a network or within a geographic region.

**d. Actions Implemented**

The Plan implemented the following actions in the last year:

- Expanded telemedicine program to include more services.
- Continues access-based review for approval of out of network requests for psychiatrists.

**g. Actions Recommended**

We recommend the following actions for 2020/2021 to continue to work towards increasing access to providers:

- Continue measurement of appointment availability for PCP, ON.GYN and oncologists against the 90 percent goal.
- Continue access-based review for approval of out of network requests for psychiatrists.



**National Committee for Quality Assurance**  
has awarded

*Blue Cross and Blue Shield of Vermont*

*Exchange EPO*

an accreditation status of

**Accredited**

for service and clinical quality that meet or exceed NCQA's rigorous requirements for consumer protection and quality improvement.



*David Choi, MD*  
CHAIR, BOARD OF DIRECTORS

*Margaret S. J. K.*  
PRESIDENT

*[Signature]*  
CHAIR, REVIEW OVERSIGHT COMMITTEE

**11/05/2020**

DATE GRANTED

**11/05/2023**

EXPIRATION DATE



**National Committee for Quality Assurance**  
has awarded

*Blue Cross and Blue Shield of Vermont*

*Commercial HMO/POS/PPO/EPO Combined*

an accreditation status of

**Accredited**

for service and clinical quality that meet or exceed NCQA's rigorous requirements for consumer protection and quality improvement.



*David Choi, MD*

CHAIR, BOARD OF DIRECTORS

*Margaret S. J. K.*

PRESIDENT

*[Signature]*

CHAIR, REVIEW OVERSIGHT COMMITTEE

**11/05/2020**

DATE GRANTED

**11/05/2023**

EXPIRATION DATE

# SCORE SUMMARY OVERALL RESULTS

Organization: Blue Cross and Blue Shield of Vermont  
 License: 91552

**ⓘ A manual browser refresh may be required to view updated scores**

License Selector

Blue Cross and Blue Shield of Vermont (P) - 91552 ▾

Results and Scores Selector

**Results and Scores Selector** Overall Results and Summary of Scores ▾

VIEW SCORING SUMMARY FOR

**Evaluation product** Renewal Survey ▾

**Units of Assessment** Commercial HMO/POS/PPO/EPO Combined ▾

[VIEW must-pass results](#)

NCQA STATUS: **Accredited**  
 HEDIS CAHPS Submitted: Yes  
 HPR RATING: ★★★★★ ▾

**ⓘ Warning: Must Pass >= 3 may be subject to denial by ROC**

CATEGORY SCORING THRESHOLDS ▾

CATEGORY	CATEGORY RESULT	COUNT OF APPLICABLE POINTS FOR CATEGORY (TOTAL POSSIBLE)	COUNT OF POINTS (POINTS RECEIVED)	80% AND ABOVE THRESHOLD POINTS	Below 80% AND ABOVE 55% THRESHOLD POINTS	Below 55% THRESHOLD POINTS
QI - Quality Management and Improvement	Met	11.00	11.00	8.80	6.05	5.94
PHM - Population Health Management	Met	21.00	21.00	16.80	11.55	11.34
NET - Network Management	Met	24.00	21.00	19.20	13.20	12.96
UM - Utilization Management	Met	41.00	41.00	32.80	22.55	22.14
CR - Credentialing	Met	13.00	13.00	10.40	7.15	7.02
ME - Member Experience	Met	24.00	19.50	19.20	13.20	12.96

CATEGORY/STANDARD ROLLUP SCORES ▾



CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
QI	QI1	Program Structure and Operations	Met	Met		4.00	4.00
QI	QI2	Health Services Contracting	NA	NA		NA	0.00
QI	QI3	Continuity and Coordination of Medical Care	Met	Met		4.00	4.00
QI	QI4	Continuity and Coordination Between Medical Care and Behavioral Healthcare	Met	Met		3.00	3.00
QI	QI5	Delegation of QI	NA	NA		NA	0.00
					<b>Category Score</b>	11.00	11.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
PHM	PHM1	PHM Strategy	Met	Met		3.00	3.00
PHM	PHM2	Population Identification	Met	Met		4.00	4.00
PHM	PHM3	Delivery System Supports	Met	Met		2.00	2.00
PHM	PHM4	Wellness and Prevention	Met	Met		1.00	1.00
PHM	PHM5	Complex Case Management	Met	Met		6.00	6.00
PHM	PHM6	Population Health Management Impact	Met	Met		2.00	2.00
PHM	PHM7	Delegation of PHM	Met	Met		3.00	3.00
					<b>Category Score</b>	21.00	21.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
NET	NET1	Availability of Practitioners	Met	Met		4.00	4.00
NET	NET2	Accessibility of Services	Met	Met		3.00	3.00
NET	NET3	Assessment of Network Adequacy	Met	Met		4.00	6.00
NET	NET4	Continued Access to Care	Met	Met		2.00	2.00
NET	NET5	Physician and Hospital Directories	Met	Met		5.00	6.00
NET	NET6	Delegation of NET	Met	Met		3.00	3.00
					<b>Category Score</b>	21.00	24.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
UM	UM1	Program Structure	Met	Met		1.00	1.00
UM	UM2	Clinical Criteria for UM Decisions	Met	Met		2.00	2.00
UM	UM3	Communication Services	Met	Met		1.00	1.00
UM	UM4	Appropriate Professionals	Met	Met		4.00	4.00
UM	UM5	Timeliness of UM Decisions	Met	Met		4.00	4.00
UM	UM6	Clinical Information	NA	Met		3.00	3.00
UM	UM7	Denial Notices	NA	Met		9.00	9.00
UM	UM8	Policies for Appeals	NA	NA		NA	0.00
UM	UM9	Appropriate Handling of Appeals	NA	Met	✓	5.00	5.00
UM	UM10	Evaluation of New Technology	Met	Met		2.00	2.00
UM	UM11	Procedures for Pharmaceutical Management	Met	Met		5.00	5.00
UM	UM12	UM System Controls	Met	Met		2.00	2.00
UM	UM13	Delegation of UM	Met	Met		3.00	3.00
					<b>Category Score</b>	41.00	41.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
CR	CR1	Credentialing Policies	Met	Met		1.00	1.00
CR	CR2	Credentialing Committee	Met	Met		1.00	1.00
CR	CR3	Credentialing Verification	NA	Met		3.00	3.00
CR	CR4	Recredentialing Cycle Length	NA	Met		1.00	1.00
CR	CR5	Ongoing Monitoring and Interventions	Met	Met		2.00	2.00
CR	CR7	Assessment of Organizational Providers	Met	Met		2.00	2.00
CR	CR8	Delegation of CR	Met	Met		3.00	3.00
					<b>Category Score</b>	13.00	13.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
ME	ME1	Statement of Members' Rights and Responsibilities	Met	Met		1.00	1.00
ME	ME2	Subscriber Information	Met	Met		3.00	3.00
ME	ME3	Marketing Information	Met	Met		2.00	3.00
ME	ME5	Pharmacy Benefit Information	Met	Met		2.00	2.00
ME	ME6	Personalized Information on Health Plan Services	Met	Met		4.00	4.00
ME	ME7	Member Experience	Met	Met		5.00	8.00
ME	ME8	Delegation of ME	Met	Met	✓	2.50	3.00
					<b>Category Score</b>	19.50	24.00

# SCORE SUMMARY OVERALL RESULTS

Organization: The Vermont Health Plan  
 License: 91553

**ⓘ A manual browser refresh may be required to view updated scores**

License Selector

The Vermont Health Plan (s) - 91553 ▼

Results and Scores Selector

**Results and Scores Selector** Overall Results and Summary of Scores ▼

VIEW SCORING SUMMARY FOR

**Evaluation product** Renewal Survey ▼

**Units of Assessment** Commercial HMO/POS Combined ▼

[VIEW must-pass results](#)

NCQA STATUS: **Accredited**  
 HEDIS CAHPS Submitted: Yes  
 HPR RATING: ★★★★★ ▼

**ⓘ Warning: Must Pass >= 3 may be subject to denial by ROC**

CATEGORY SCORING THRESHOLDS ▼

CATEGORY	CATEGORY RESULT	COUNT OF APPLICABLE POINTS FOR CATEGORY (TOTAL POSSIBLE)	COUNT OF POINTS (POINTS RECEIVED)	80% AND ABOVE THRESHOLD POINTS	Below 80% AND ABOVE 55% THRESHOLD POINTS	Below 55% THRESHOLD POINTS
QI - Quality Management and Improvement	Met	11.00	11.00	8.80	6.05	5.94
PHM - Population Health Management	Met	21.00	21.00	16.80	11.55	11.34
NET - Network Management	Met	21.00	18.00	16.80	11.55	11.34
UM - Utilization Management	Met	41.00	41.00	32.80	22.55	22.14
CR - Credentialing	Met	13.00	13.00	10.40	7.15	7.02
ME - Member Experience	Met	24.00	19.50	19.20	13.20	12.96

CATEGORY/STANDARD ROLLUP SCORES ▼

--

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
QI	QI1	Program Structure and Operations	Met	Met		4.00	4.00
QI	QI2	Health Services Contracting	NA	NA		NA	0.00
QI	QI3	Continuity and Coordination of Medical Care	Met	Met		4.00	4.00
QI	QI4	Continuity and Coordination Between Medical Care and Behavioral Healthcare	Met	Met		3.00	3.00
QI	QI5	Delegation of QI	NA	NA		NA	0.00
					<b>Category Score</b>	11.00	11.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
PHM	PHM1	PHM Strategy	Met	Met		3.00	3.00
PHM	PHM2	Population Identification	Met	Met		4.00	4.00
PHM	PHM3	Delivery System Supports	Met	Met		2.00	2.00
PHM	PHM4	Wellness and Prevention	Met	Met		1.00	1.00
PHM	PHM5	Complex Case Management	Met	Met		6.00	6.00
PHM	PHM6	Population Health Management Impact	Met	Met		2.00	2.00
PHM	PHM7	Delegation of PHM	Met	Met		3.00	3.00
					<b>Category Score</b>	21.00	21.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
NET	NET1	Availability of Practitioners	Met	Met		4.00	4.00
NET	NET2	Accessibility of Services	Met	Met		3.00	3.00
NET	NET3	Assessment of Network Adequacy	Met	Met		4.00	6.00
NET	NET4	Continued Access to Care	Met	Met		2.00	2.00
NET	NET5	Physician and Hospital Directories	Met	Met		5.00	6.00
NET	NET6	Delegation of NET	Met	NA		NA	0.00
					<b>Category Score</b>	18.00	21.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
UM	UM1	Program Structure	Met	Met		1.00	1.00
UM	UM2	Clinical Criteria for UM Decisions	Met	Met		2.00	2.00
UM	UM3	Communication Services	Met	Met		1.00	1.00
UM	UM4	Appropriate Professionals	Met	Met		4.00	4.00
UM	UM5	Timeliness of UM Decisions	Met	Met		4.00	4.00
UM	UM6	Clinical Information	NA	Met		3.00	3.00
UM	UM7	Denial Notices	NA	Met		9.00	9.00
UM	UM8	Policies for Appeals	NA	NA		NA	0.00
UM	UM9	Appropriate Handling of Appeals	NA	Met		5.00	5.00
UM	UM10	Evaluation of New Technology	Met	Met		2.00	2.00
UM	UM11	Procedures for Pharmaceutical Management	Met	Met		5.00	5.00
UM	UM12	UM System Controls	Met	Met		2.00	2.00
UM	UM13	Delegation of UM	Met	Met		3.00	3.00
					<b>Category Score</b>	41.00	41.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
CR	CR1	Credentialing Policies	Met	Met		1.00	1.00
CR	CR2	Credentialing Committee	Met	Met		1.00	1.00
CR	CR3	Credentialing Verification	NA	Met		3.00	3.00
CR	CR4	Recredentialing Cycle Length	NA	Met		1.00	1.00
CR	CR5	Ongoing Monitoring and Interventions	Met	Met		2.00	2.00
CR	CR7	Assessment of Organizational Providers	Met	Met		2.00	2.00
CR	CR8	Delegation of CR	Met	Met		3.00	3.00
					<b>Category Score</b>	13.00	13.00

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE I
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
ME	ME1	Statement of Members' Rights and Responsibilities	Met	Met		1.00	1.00
ME	ME2	Subscriber Information	Met	Met		3.00	3.00
ME	ME3	Marketing Information	Met	Met		2.00	3.00
ME	ME5	Pharmacy Benefit Information	Met	Met		2.00	2.00
ME	ME6	Personalized Information on Health Plan Services	Met	Met		4.00	4.00
ME	ME7	Member Experience	Met	Met		5.00	8.00
ME	ME8	Delegation of ME	Met	Met		2.50	3.00
					<b>Category Score</b>	19.50	24.00

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ANEMIA	ARANESP	SOLN	DARBEPOETIN ALFA SOLN INJ	
ANEMIA	ARANESP	SOSY	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE	
ANEMIA	EPOGEN	SOLN	EPOETIN ALFA INJ	X
ANEMIA	PROCRIT	SOLN	EPOETIN ALFA INJ	X
ANEMIA	REBLOZYL	SOLR	LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ	
ANEMIA	RETACRIT	SOLN	EPOETIN ALFA-EPBX INJ	
ANTI-GOUT AGENT	KRYSTEXXA	SOLN	PEGLOTICASE INJ (FOR IV INFUSION)	
ANTI-INFECTIVE	PREVMIS	SOLN	LETERMOVIR IV SOLN	
ANTI-INFECTIVE	PREVMIS	TABS	LETERMOVIR TAB	
ASTHMA	CINQAIR	SOLN	RESLIZUMAB IV INFUSION SOLN	
ASTHMA	FASENRA	SOSY	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
ASTHMA	FASENRA PEN	SOAJ	BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR	
ASTHMA	NUCALA	SOAJ	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR	
ASTHMA	NUCALA	SOLR	MEPOLIZUMAB FOR INJ	
ASTHMA	NUCALA	SOSY	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE	
ASTHMA	XOLAIR	SOLR	OMALIZUMAB FOR INJ	
ASTHMA	XOLAIR	SOSY	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
CARDIOVASCULAR	VYNDAMAX	CAPS	TAFAMIDIS CAP	
CARDIOVASCULAR	VYNDAQEL	CAPS	TAFAMIDIS MEGLUMINE (CARDIAC) CAP	
CENTRAL NERVOUS SYSTEM AGENTS	AUSTEDO	TABS	DEUTETRABENAZINE TAB	
CENTRAL NERVOUS SYSTEM AGENTS	ENSPRYNG	SOSY	SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE	
CENTRAL NERVOUS SYSTEM AGENTS	HETLIOZ	CAPS	TASIMELTEON CAPSULE	
CENTRAL NERVOUS SYSTEM AGENTS	HETLIOZ LQ	SUSP	TASIMELTEON ORAL SUSP	
CHEMOTHERAPY PROTECTANT	AMIFOSTINE	SOLR	AMIFOSTINE CRYSTALLINE FOR INJ	
CHEMOTHERAPY PROTECTANT	ELITEK	SOLR	RASBURICASE FOR IV SOLN	
CHEMOTHERAPY PROTECTANT	ETHYOL	SOLR	AMIFOSTINE CRYSTALLINE FOR INJ	
CHEMOTHERAPY PROTECTANT	LEVOLEUCOVOR	SOLN	LEVOLEUCOVORIN CALCIUM IV SOLN PF (BASE EQUIV)	
CYSTIC FIBROSIS	BETHKIS	NEBU	TOBRAMYCIN NEBU SOLN	X
CYSTIC FIBROSIS	KALYDECO	PACK	IVACAFTOR PACKET	
CYSTIC FIBROSIS	KALYDECO	TABS	IVACAFTOR TAB	
CYSTIC FIBROSIS	KITABIS PAK	NEBU	TOBRAMYCIN NEBU SOLN	X
CYSTIC FIBROSIS	ORKAMBI	PACK	LUMACAFOR-IVACAFTOR GRANULES PACKET	
CYSTIC FIBROSIS	ORKAMBI	TABS	LUMACAFOR-IVACAFTOR TAB	
CYSTIC FIBROSIS	PULMOZYME	SOLN	DORNASE ALFA INHAL SOLN	



Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
CYSTIC FIBROSIS	SYMDEKO	TBPK	TEZACAFTOR-IVACAFTOR & IVACAFTOR TAB TBPK	
CYSTIC FIBROSIS	TOBI	NEBU	TOBRAMYCIN NEBU SOLN	X
CYSTIC FIBROSIS	TOBI PODHALR	CAPS	TOBRAMYCIN INHAL CAP	
CYSTIC FIBROSIS	TOBRAMYCIN	NEBU	TOBRAMYCIN NEBU SOLN	(300mg/5ml)
CYSTIC FIBROSIS	TRIKAFTA	TBPK	ELEXACAF-TEZACAF-IVACAF & IVACAFTOR TBPK	
DIAGNOSTIC	ACTHREL	SOLR	CORTICORELIN OVINE TRIFLUTATE FOR IV INJ	
ENDOCRINE	BYNFEZIA PEN	SOPN	OCTREOTIDE ACETATE SOLN PEN-INJECTOR	X
ENDOCRINE	CLOVIQUE	CAPS	TRIENTINE HCL CAP	
ENDOCRINE	CUPRID	CAPS	TRIENTINE HCL CAP	
ENDOCRINE	CUPRIMINE	CAPS	PENICILLAMINE CAP	
ENDOCRINE	DELTA-LUTIN	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	DEPEN TITRA	TABS	PENICILLAMINE TAB	
ENDOCRINE	DEPROLUTIN	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	D-PENAMINE	TABS	PENICILLAMINE TAB	
ENDOCRINE	DURALUTIN	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	EGRIFTA	SOLR	TESAMORELIN ACETATE FOR INJ	
ENDOCRINE	EGRIFTA SV	SOLR	TESAMORELIN ACETATE FOR INJ	
ENDOCRINE	FIRMAGON	SOLR	DEGARELIX ACETATE FOR INJ	
ENDOCRINE	GESTEROL LA	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYDROGEST	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYDROXY CAPR	SOLN	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYDROXYPROG	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYLUTIN	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYPROGEST	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYPROVAL	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	HYPROVAL PA	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	JYNARQUE	TABS	TOLVAPTAN TAB	
ENDOCRINE	JYNARQUE	TBPK	TOLVAPTAN TAB THERAPY PACK	
ENDOCRINE	KUVAN	PACK	SAPROPTERIN DIHYDROCHLORIDE POWDER PACKET	X
ENDOCRINE	KUVAN	TABS	SAPROPTERIN DIHYDROCHLORIDE TAB	X
ENDOCRINE	LUPANETA	KIT	LEUPROLIDE INJ& NORETHINDRONE TAB KIT	
ENDOCRINE	LUPRON DEPOT	INJ	LEUPROLIDE ACETATE FOR INJ	
ENDOCRINE	MAKENA	OIL	HYDROXYPROGESTERONE CAPROATE IM IN OIL	
ENDOCRINE	MAKENA	SOAJ	HYDROXYPROGESTERONE CAPROATE SOLN AUTO-INJECTOR	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ENDOCRINE	NITYR	TABS	NITISINONE TAB	
ENDOCRINE	OCTREOTIDE	SOLN	OCTREOTIDE ACETATE INJ	
ENDOCRINE	PARSABIV	SOLN	ETELCALCETIDE HCL IV SOLUTION	
ENDOCRINE	PENICILLAMIN	CAPS	PENICILLAMINE CAP	
ENDOCRINE	PENICILLAMIN	TABS	PENICILLAMINE TAB	
ENDOCRINE	SAMSCA	TABS	TOLVAPTAN TAB	
ENDOCRINE	SANDOSTATIN	INJ	OCTREOTIDE ACETATE INJ	X
ENDOCRINE	SANDOSTATIN	KIT	OCTREOTIDE ACETATE FOR IM INJ KIT	X
ENDOCRINE	SANDOSTATIN	SOLN	OCTREOTIDE ACETATE INJ	X
ENDOCRINE	SAPROPTERIN	PACK	SAPROPTERIN DIHYDROCHLORIDE POWDER PACKET	
ENDOCRINE	SAPROPTERIN	TABS	SAPROPTERIN DIHYDROCHLORIDE TAB	
ENDOCRINE	SOMATULINE	SOLN	LANREOTIDE ACETATE EXTENDED RELEASE INJ	
ENDOCRINE	SOMAVERT	SOLR	PEGVISOMANT FOR INJ	
ENDOCRINE	SYPRINE	CAPS	TRIENTINE HCL CAP	
ENDOCRINE	THYROGEN	SOLR	THYROTROPIN ALFA FOR INJMG	
ENDOCRINE	TOLVAPTAN	TABS	TOLVAPTAN TAB	
ENDOCRINE	TRIENTINE	CAPS	TRIENTINE HCL CAP	
ENZYME THERAPY	ALDURAZYME	SOLN	LARONIDASE SOLN FOR IV INFUSION	
ENZYME THERAPY	BUPHENYL	POWD	SODIUM PHENYL BUTYRATE ORAL POWDER	
ENZYME THERAPY	BUPHENYL	TABS	SODIUM PHENYL BUTYRATE TAB	
ENZYME THERAPY	CERDELGA	CAPS	ELIGLUSTAT TARTRATE CAP	
ENZYME THERAPY	CEREZYME	SOLR	IMIGLUCERASE FOR INJ	
ENZYME THERAPY	ELAPRASE	SOLN	IDURSULFASE SOLN FOR IV INFUSION	
ENZYME THERAPY	FABRAZYME	SOLR	AGALSIDASE BETA FOR IV SOLN	
ENZYME THERAPY	GLASSIA	SOLN	ALPHA1-PROTEINASE INHIBITOR (HUMAN) INJ	
ENZYME THERAPY	KANUMA	SOLN	SEBELIPASE ALFA IV SOLN	
ENZYME THERAPY	LUMIZYME	SOLR	ALGLUCOSIDASE ALFA FOR IV SOLN	
ENZYME THERAPY	MYOZYME	SOLR	ALGLUCOSIDASE ALFA FOR IV SOLN	
ENZYME THERAPY	PALYNZIQ	SOSY	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE	
ENZYME THERAPY	PHENYL BUTYRA	POWD	SODIUM PHENYL BUTYRATE ORAL POWDER	
ENZYME THERAPY	SODIUM PHENY	TABS	SODIUM PHENYL BUTYRATE TAB	
ENZYME THERAPY	VPRIV	SOLR	VELAGLUCERASE ALFA FOR INJ	
GASTROINTESTINAL AGENTS	XERMELO	TABS	TELOTRISTAT ETHYL TAB (AS TELOTRISTAT ETIPRATE)	
GROWTH HORMONE DEFICIENCY	GENOTROPIN	SOLR	SOMATROPIN FOR SUBCUTANEOUS INJ	X

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
GROWTH HORMONE DEFICIENCY	HUMATROPE	SOLR	SOMATROPIN FOR INJ	X
GROWTH HORMONE DEFICIENCY	INCRELEX	SOLN	MECASERMIN INJ	
GROWTH HORMONE DEFICIENCY	NORDITROPIN	SOLN	SOMATROPIN INJ	
GROWTH HORMONE DEFICIENCY	NORDITROPIN	SOLR	SOMATROPIN FOR INJ	
GROWTH HORMONE DEFICIENCY	NORDITROPIN	SOPN	SOMATROPIN SOLUTION PEN-INJECTOR	
GROWTH HORMONE DEFICIENCY	NUTROPIN	SOLR	SOMATROPIN FOR SUBCUTANEOUS INJ	
GROWTH HORMONE DEFICIENCY	NUTROPIN AQ	SOLN	SOMATROPIN INJ	
GROWTH HORMONE DEFICIENCY	NUTROPIN AQ	SOPN	SOMATROPIN SOLUTION PEN-INJECTOR	
GROWTH HORMONE DEFICIENCY	OMNITROPE	SOCT	SOMATROPIN SOLUTION CARTRIDGE	X
GROWTH HORMONE DEFICIENCY	OMNITROPE	SOLN	SOMATROPIN INJ	X
GROWTH HORMONE DEFICIENCY	OMNITROPE	SOLR	SOMATROPIN FOR INJ	X
GROWTH HORMONE DEFICIENCY	SAIZEN	SOLR	SOMATROPIN (NON-REFRIGERATED) FOR INJ	X
GROWTH HORMONE DEFICIENCY	SAIZENPREP	SOLR	SOMATROPIN (NON-REFRIGERATED) FOR INJ	X
GROWTH HORMONE DEFICIENCY	SEROSTIM	SOLR	SOMATROPIN FOR INJ	
GROWTH HORMONE DEFICIENCY	TEV-TROPIN	SOLR	SOMATROPIN FOR SUBCUTANEOUS INJ	
GROWTH HORMONE DEFICIENCY	ZOMACTON	SOLR	SOMATROPIN FOR SUBCUTANEOUS INJ	X
GROWTH HORMONE DEFICIENCY	ZORBIVE	SOLR	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ	
HEMATOLOGICAL AGENTS	ADAKVEO	SOLN	CRIZANLIZUMAB-TMCA IV SOLN	
HEMATOLOGICAL AGENTS	ATNATIV	SOLR	ANTITHROMBIN III (HUMAN) FOR INJ	
HEMATOLOGICAL AGENTS	FIBRYGA	SOLR	FIBRINOGEN CONC (HUMAN) INJ	
HEMATOLOGICAL AGENTS	MOZOBIL	SOLN	PLERIXAFOR SUBCUTANEOUS INJ	
HEMATOLOGICAL AGENTS	NEUMEGA	SOLR	OPRELVEKIN FOR INJ	
HEMATOLOGICAL AGENTS	NPLATE	SOLR	ROMIPLOSTIM FOR INJ	
HEMATOLOGICAL AGENTS	PANHEMATIN	SOLR	HEMIN FOR INJ	
HEMATOLOGICAL AGENTS	PROMACTA	PACK	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP	
HEMATOLOGICAL AGENTS	PROMACTA	TABS	ELTROMBOPAG OLAMINE TAB	
HEMATOLOGICAL AGENTS	RIASTAP	SOLR	FIBRINOGEN CONC (HUMAN) INJ	
HEMATOLOGICAL AGENTS	SOLIRIS	SOLN	ECULIZUMAB IV SOLN (FOR INFUSION)	
HEMATOLOGICAL AGENTS	TAVALISSE	TABS	FOSTAMATINIB DISODIUM TAB	
HEMATOLOGICAL AGENTS	THROMBAT III	SOLR	ANTITHROMBIN III (HUMAN) FOR INJ	
HEMATOLOGICAL AGENTS	ULTOMIRIS	SOLN	RAVULIZUMAB-CWVZ IV SOLN	
HEMOPHILIA	ADVATE	SOLR	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ	
HEMOPHILIA	ADYNOVATE	SOLR	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ	
HEMOPHILIA	AFSTYLA	KIT	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
HEMOPHILIA	ALPHANATE	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	ALPHANINE SD	SOLR	COAGULATION FACTOR IX FOR INJ	
HEMOPHILIA	ALPROLIX	SOLR	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ	
HEMOPHILIA	AUTOPLEX T	SOLR	ANTIINHIBITOR COAGULANT COMPLEX FOR INJ	
HEMOPHILIA	BEBULIN	SOLR	FACTOR IX COMPLEX FOR INJ	
HEMOPHILIA	BEBULIN VH	SOLR	FACTOR IX COMPLEX FOR INJ	
HEMOPHILIA	BENEFIX	KIT	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT	
HEMOPHILIA	BENEFIX	SOLR	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ	
HEMOPHILIA	BIOCLATE	SOLR	ANTIHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ	
HEMOPHILIA	COAGADEX	SOLR	COAGULATION FACTOR X (HUMAN) FOR INJ	
HEMOPHILIA	CORIFACT	KIT	FACTOR XIII CONCENTRATE (HUMAN) FOR INJ KIT	
HEMOPHILIA	ELOCTATE	SOLR	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIIIIC) FOR INJ	
HEMOPHILIA	ESPEROCT	SOLR	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ	X
HEMOPHILIA	FEIBA	SOLR	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN	
HEMOPHILIA	FEIBA NF	SOLR	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN	
HEMOPHILIA	FEIBA VH	SOLR	ANTIINHIBITOR COAGULANT COMPLEX FOR INJ	
HEMOPHILIA	GENARC	SOLR	ANTIHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ	
HEMOPHILIA	HELIXATE	KIT	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT	
HEMOPHILIA	HELIXATE FS	KIT	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT	
HEMOPHILIA	HEMLIBRA	SOLN	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN	
HEMOPHILIA	HEMOPIL M	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	HT FACTOR HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	HT FACTOR II	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	HUMATE-P	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	HUMATE-P HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	IDELVION	SOLR	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ	
HEMOPHILIA	IXINITY	SOLR	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ	
HEMOPHILIA	JIVI	SOLR	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII PEG-AUCL) FOR INJ	
HEMOPHILIA	KOATE	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-DVI	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-HP	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-HP HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-HS	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-HS HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
HEMOPHILIA	KOATE-HT	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOATE-HT HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	KOGENATE	KIT	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT	
HEMOPHILIA	KOGENATE	SOLR	ANTIHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ	
HEMOPHILIA	KOGENATE FS	KIT	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT	
HEMOPHILIA	KONYNE 80	SOLR	FACTOR IX COMPLEX FOR INJ	
HEMOPHILIA	KONYNE-HT	SOLR	FACTOR IX COMPLEX FOR INJ	
HEMOPHILIA	KOVALTRY	SOLR	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ	
HEMOPHILIA	MELATE	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	MONARC-M	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	MONOCLATE	KIT	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ KIT	
HEMOPHILIA	MONOCLATE HU	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	MONOCLATE-P	KIT	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ KIT	
HEMOPHILIA	MONONINE	SOLR	COAGULATION FACTOR IX FOR INJ	
HEMOPHILIA	NOVOEIGHT	SOLR	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ	
HEMOPHILIA	NOVOSEVEN	SOLR	COAGULATION FACTOR VIIA (RECOMB) FOR INJ	
HEMOPHILIA	NOVOSEVEN RT	SOLR	COAGULATION FACTOR VIIA (RECOMB) FOR INJ	
HEMOPHILIA	NUWIQ	KIT	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT	
HEMOPHILIA	NUWIQ	SOLR	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII,SIM) FOR INJ	
HEMOPHILIA	PROFILATE-HP	SOLR	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ	
HEMOPHILIA	PROFILNINE	SOLR	FACTOR IX COMPLEX FOR INJ	
HEMOPHILIA	REBINYN	SOLR	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED FOR INJ	
HEMOPHILIA	RECOMBIMATE	SOLR	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ	
HEMOPHILIA	REFACTO	KIT	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT	
HEMOPHILIA	RIXUBIS	SOLR	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ	
HEMOPHILIA	SEVENFACT	SOLR	COAGULATION FACTOR VIIA (RECOM)-JNCW FOR INJ	
HEMOPHILIA	TRETEN	SOLR	COAGULATION FACTOR XIII A-SUBUNIT FOR INJ	
HEMOPHILIA	VONVENDI	SOLR	VON WILLEBRAND FACTOR (RECOMBINANT) FOR INJ	
HEMOPHILIA	WILATE	KIT	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ	
HEMOPHILIA	WILATE	SOLR	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ	
HEMOPHILIA	XYNTHA	KIT	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT	
HEMOPHILIA	XYNTHA SOLOF	KIT	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT	
HEPATITIS B	ADEFOV DIPIV	TABS	ADEFOVIR DIPIVOXIL TAB	
HEPATITIS B	BARACLUE	SOLN	ENTECAVIR ORAL SOLN	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
HEPATITIS B	BARACLUDE	TABS	ENTECAVIR TAB	X
HEPATITIS B	ENTECAVIR	TABS	ENTECAVIR TAB	
HEPATITIS B	EPIVIR HBV	SOLN	LAMIVUDINE ORAL SOLN (HBV)	
HEPATITIS B	EPIVIR HBV	TABS	LAMIVUDINE TAB	
HEPATITIS B	HEPSERA	TABS	ADEFOVIR DIPIVOXIL TAB	
HEPATITIS B	LAMIVUDINE	TABS	LAMIVUDINE TAB(HBV)	
HEPATITIS B	TYZEKA	TABS	TELBIVUDINE TAB	
HEPATITIS B	VEMLIDY	TABS	TENOFOVIR ALAFENAMIDE FUMARATE TAB	
HEPATITIS C	COPEGUS	TABS	RIBAVIRIN TAB	
HEPATITIS C	DAKLINZA	TABS	DACLATASVIR DIHYDROCHLORIDE TAB	
HEPATITIS C	EPCLUSA	TABS	SOFOSBUVIR-VELPATASVIR TAB	
HEPATITIS C	HARVONI	PACK	LEDIPASVIR-SOFOSBUVIR PELLETT PACK	
HEPATITIS C	HARVONI	TABS	LEDIPASVIR-SOFOSBUVIR TAB	
HEPATITIS C	LEDIP-SOFOSB	TABS	LEDIPASVIR-SOFOSBUVIR TAB	X
HEPATITIS C	MAVYRET	TABS	GLECAPREVIR-PIBRENTASVIR TAB	
HEPATITIS C	MODERIBA	TABS	RIBAVIRIN TAB	
HEPATITIS C	MODERIBA	TBPK	RIBAVIRIN TAB PACK	
HEPATITIS C	OLYSIO	CAPS	SIMEPREVIR SODIUM CAP	
HEPATITIS C	PEGASYS	KIT	PEGINTERFERON ALFA-2A INJ KIT	
HEPATITIS C	PEGASYS	SOLN	PEGINTERFERON ALFA-2A INJ	
HEPATITIS C	PEG-INTRON	KIT	PEGINTERFERON ALFA-2B FOR INJ KIT	
HEPATITIS C	PEGINTRON	KIT	PEGINTERFERON ALFA-2B FOR INJ KIT	
HEPATITIS C	REBETOL	CAPS	RIBAVIRIN CAP	
HEPATITIS C	REBETOL	SOLN	RIBAVIRIN SOLN 40	
HEPATITIS C	RIBAPAK	TABS	RIBAVIRIN TAB	
HEPATITIS C	RIBAPAK	TBPK	RIBAVIRIN TAB PACK	
HEPATITIS C	RIBASPHERE	CAPS	RIBAVIRIN CAP	
HEPATITIS C	RIBASPHERE	TABS	RIBAVIRIN TAB	
HEPATITIS C	RIBATAB	TABS	RIBAVIRIN TAB	
HEPATITIS C	RIBATAB	TBPK	RIBAVIRIN TAB THERAPY PACK	
HEPATITIS C	RIBAVIRIN	CAPS	RIBAVIRIN CAP	
HEPATITIS C	RIBAVIRIN	TABS	RIBAVIRIN TAB	
HEPATITIS C	SOFOS/VELPAT	TABS	SOFOSBUVIR-VELPATASVIR TAB	X
HEPATITIS C	SOVALDI	PACK	SOFOSBUVIR PELLETT PACK	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
HEPATITIS C	SOVALDI	TABS	SOFOSBUVIR TAB	
HEPATITIS C	TECHNIVIE	TABS	OMBITASVIR-PARITAPREVIR-RITONAVIR TAB	
HEPATITIS C	VIEKIRA PAK	TBPK	OMBITAS-PARITAPRE-RITON & DASAB TAB PAK	
HEPATITIS C	VIEKIRA XR	TB24	DASAB-OMBIT-PARITAP-RITON TAB ER 24HR	
HEPATITIS C	VOSEVI	TABS	SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR TAB	
HEPATITIS C	ZEPATIER	TABS	ELBASVIR-GRAZOPREVIR TAB	
HEREDITARY ANGIOEDEMA	BERINERT	KIT	C1 ESTERASE INHIBITOR (HUMAN) FOR IV INJ KIT	
HEREDITARY ANGIOEDEMA	CINRYZE	SOLR	C1 ESTERASE INHIBITOR (HUMAN) FOR IV	
HEREDITARY ANGIOEDEMA	FIRAZYR	SOLN	ICATIBANT ACETATE INJ	
HEREDITARY ANGIOEDEMA	HAEGARDA	SOLR	C1 ESTERASE INHIBITOR (HUMAN) FOR SUBCUTANEOUS INJ	
HEREDITARY ANGIOEDEMA	ICATIBANT	SOLN	ICATIBANT ACETATE INJ	
HEREDITARY ANGIOEDEMA	TAKHZYRO	SOLN	LANADELUMAB-FLYO INJ	
IMMUNE GLOBULIN	ASCENIV	SOLN	IMMUNE GLOBULIN (HUMAN)-SLRA IV SOLN	X
IMMUNE GLOBULIN	BAYGAM	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	BAYRHO-D	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	BIVIGAM	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	CARIMUNE	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	CARIMUNE NF	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	CUTAQUIG	SOLN	IMMUNE GLOBULIN (HUMAN)-HIPPCUTANEOUS INJ	X
IMMUNE GLOBULIN	CUVITRU	SOLN	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ	
IMMUNE GLOBULIN	CYTOGAM	INJ	CYTOMEGALOVIRUS IMMUNE GLOBULIN (HUMAN) IV INJ	
IMMUNE GLOBULIN	FLEBOGAMMA	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	GAMASTAN	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	GAMASTAN S/D	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	GAMMAGARD	SOLN	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN	
IMMUNE GLOBULIN	GAMMAGARD	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	GAMMAGARD SD	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	GAMMAKED	SOLN	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN	
IMMUNE GLOBULIN	GAMMAPLEX	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	GAMMAR	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	GAMMAR I.V.	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	GAMMAR IM	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	GAMMAR-P IV	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	GAMULN RH	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
IMMUNE GLOBULIN	GAMULN RH HU	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	GAMUNEX	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	GAMUNEX-C	SOLN	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN	
IMMUNE GLOBULIN	HIZENTRA	SOLN	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ	
IMMUNE GLOBULIN	HIZENTRA	SOSY	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR	
IMMUNE GLOBULIN	HYPERRHO S/D	SOSY	RHO D IMMUNE GLOBULIN IM SOLN PREF SYR	
IMMUNE GLOBULIN	HYPRHO-D	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	HYPRHO-D HU	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	HYPRHO-D HU	SOLN	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	HYQVIA	KIT	IMMUN GLOB INJ -HYALURON INJ KIT	
IMMUNE GLOBULIN	IMMUGLOBIN	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	IMMUNE GLOB	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	IMMUNE GLOBU	INJ	IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	IMMUNE GLOBU	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	IVEEGAM	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	IVEEGAM EN	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	MICRHOGAM	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	MICRHOGAM	SOLN	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	MICRHOGAM PL	SOSY	RHO D IMMUNE GLOBULIN IM SOLN PREF SYR	
IMMUNE GLOBULIN	MINI-GAMULIN	SOLN	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	OCTAGAM	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	PANGLOBULIN	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	PANZYGA	SOLN	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN	X
IMMUNE GLOBULIN	POLYGAM S/D	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	PRIVIGEN	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	RHOGAM HU	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	RHOGAM HUMAN	INJ	RHO D IMMUNE GLOBULIN (HUMAN) IM INJ	
IMMUNE GLOBULIN	RHOGAM PLUS	SOSY	RHO D IMMUNE GLOBULIN IM SOLN PREF SYR	
IMMUNE GLOBULIN	SANDOGLOBULI	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	VENOBLOBUL-I	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	VENOGLOBUL-I	SOLR	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN	
IMMUNE GLOBULIN	VENOGLOBUL-S	SOLN	IMMUNE GLOBULIN (HUMAN) IV SOLN	
IMMUNE GLOBULIN	WINRHO SDF	SOLN	RHO D IMMUNE GLOBULIN (HUMAN) INJ	
IMMUNE GLOBULIN	XEMBIFY	SOLN	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ	



Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
IMMUNOLOGICAL AGENTS	ACTIMMUNE	SOLN	INTERFERON GAMMA-1B INJ	
IMMUNOLOGICAL AGENTS	BENLYSTA	SOAJ	BELIMUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR	
IMMUNOLOGICAL AGENTS	BENLYSTA	SOLR	BELIMUMAB FOR IV SOLN	
IMMUNOLOGICAL AGENTS	BENLYSTA	SOSY	BELIMUMAB SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	
IMMUNOLOGICAL AGENTS	LEMTRADA	SOLN	ALEMTUZUMAB IV INJ	
IMMUNOLOGICAL AGENTS	PALFORZIA	CSPK	PEANUT POWDER-DNFP STARTER PACK	X
IMMUNOLOGICAL AGENTS	PALFORZIA	PACK	PEANUT ALLERGEN POWDER-DNFP TITRATION PACKET	X
INFERTILITY	A.P.L.	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	BRAVELLE	SOLR	UROFOLLITROPIN PURIFIED FOR INJ	
INFERTILITY	CETROTIDE	KIT	CETRORELIX ACETATE FOR INJ KIT	X
INFERTILITY	CHOR GONADOT	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	CHOREX-10	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	CHOREX-5	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	CHORIGON	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	CHORON-10	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	CORGONJECT-5	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	EVEREADY-HCG	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	FOLLISTIM AQ	SOLN	FOLLITROPIN BETA INJ	
INFERTILITY	FOLLUTEIN	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	GANIRELIX AC	SOLN	GANIRELIX ACETATE INJ	
INFERTILITY	GANIRELIX AC	SOSY	GANIRELIX ACETATE SOLN PREFILLED SYRINGE	
INFERTILITY	GLUKOR	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	GONAL-F	KIT	FOLLITROPIN ALFA FOR INJ KIT	X
INFERTILITY	GONAL-F	SOLR	FOLLITROPIN ALFA FOR INJ	X
INFERTILITY	GONAL-F RFF	SOLN	FOLLITROPIN ALFA INJ	X
INFERTILITY	GONAL-F RFF	SOLR	FOLLITROPIN ALFA FOR SUBCUTANEOUS INJ	X
INFERTILITY	GONIC	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	HCG	SOLR	CHORIONIC GONADOTROPIN FOR INJ	
INFERTILITY	HUMEGON	SOLR	MENOTROPINS FOR INTRAMUSCULAR INJ	
INFERTILITY	LUVERIS	SOLR	LUTROPIN ALFA FOR SUBCUTANEOUS INJ	
INFERTILITY	MENOPUR	SOLR	MENOTROPINS FOR SUBCUTANEOUS INJ	
INFERTILITY	NOVAREL	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	OVIDREL	INJ	CHORIOGONADOTROPIN ALFA INJ	
INFERTILITY	OVIDREL	SOLR	CHORIOGONADOTROPIN ALFA FOR INJ	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
INFERTILITY	PERGONAL	SOLR	MENOTROPINS FOR INTRAMUSCULAR INJ	
INFERTILITY	PREGNYL	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	PROFASI	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	PROFASI HP	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFERTILITY	REPRONEX	SOLR	MENOTROPINS FOR INTRAMUSCULAR INJ	
INFERTILITY	TEGA-GONAD	SOLR	CHORIONIC GONADOTROPIN FOR IM INJ	
INFLAMMATORY CONDITIONS	ACTEMRA	SOAJ	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	ACTEMRA	SOLN	TOCILIZUMAB IV INJ	
INFLAMMATORY CONDITIONS	ACTEMRA	SOSY	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	ACTH	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	ACTH GEL	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	ACTH-80	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	ACTHAR	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	ACTHAR HP	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	AMEVIVE	SOLR	ALEFACEPT FOR IM INJ	
INFLAMMATORY CONDITIONS	AVSOLA	SOLR	INFLIXIMAB-AXXQ FOR IV INJ	
INFLAMMATORY CONDITIONS	CIMZIA	KIT	CERTOLIZUMAB PEGOL FOR INJ KIT	
INFLAMMATORY CONDITIONS	CIMZIA PREFL	KIT	CERTOLIZUMAB PEGOL INJ KIT	
INFLAMMATORY CONDITIONS	CIMZIA START	KIT	CERTOLIZUMAB PEGOL INJ KIT	
INFLAMMATORY CONDITIONS	CORTROPHEN	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	COSENTYX	SOSY	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	X
INFLAMMATORY CONDITIONS	COSENTYX PEN	SOAJ	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR	X
INFLAMMATORY CONDITIONS	DUPIXENT	SOPN	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR	
INFLAMMATORY CONDITIONS	DUPIXENT	SOSY	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	ENBREL	SOLN	ETANERCEPT SUBCUTANEOUS INJ	
INFLAMMATORY CONDITIONS	ENBREL	SOLR	ETANERCEPT FOR SUBCUTANEOUS INJ	
INFLAMMATORY CONDITIONS	ENBREL	SOSY	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	ENBREL MINI	SOCT	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE	
INFLAMMATORY CONDITIONS	ENBREL SRCLK	SOAJ	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	ENTYVIO	SOLR	VEDOLIZUMAB FOR IV SOLUTION	
INFLAMMATORY CONDITIONS	HUMIRA	KIT	ADALIMUMAB INJ KIT	
INFLAMMATORY CONDITIONS	HUMIRA	PSKT	ADALIMUMAB PREFILLED SYRINGE KIT	
INFLAMMATORY CONDITIONS	HUMIRA PEDIA	PSKT	ADALIMUMAB PREFILLED SYRINGE KIT	
INFLAMMATORY CONDITIONS	HUMIRA PEN	PNKT	ADALIMUMAB PEN-INJECTOR KIT	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
INFLAMMATORY CONDITIONS	ILUMYA	SOSY	TILDRAKIZUMAB-ASMN SUBCUTANEOUS SOLN PREF SYRINGE	
INFLAMMATORY CONDITIONS	INFLECTRA	SOLR	INFLIXIMAB-DYYB FOR IV INJ	
INFLAMMATORY CONDITIONS	KEVZARA	SOAJ	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	KEVZARA	SOSY	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	OLUMIANT	TABS	BARICITINIB TAB	X
INFLAMMATORY CONDITIONS	ORENCIA	SOLR	ABATACEPT FOR IV SOLN	
INFLAMMATORY CONDITIONS	ORENCIA	SOSY	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	ORENCIA CLCK	SOAJ	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	OTEZLA	TABS	APREMILAST TAB	
INFLAMMATORY CONDITIONS	OTEZLA	TBPK	APREMILAST TAB STARTER THERAPY PACK	
INFLAMMATORY CONDITIONS	REMICADE	SOLR	INFLIXIMAB FOR IV INJ	X
INFLAMMATORY CONDITIONS	RENFLEXIS	SOLR	INFLIXIMAB-ABDA FOR IV INJ	X
INFLAMMATORY CONDITIONS	RESP CORTICO	GEL	CORTICOTROPIN INJ GEL	
INFLAMMATORY CONDITIONS	RIDAURA	CAPS	AURANOFIN CAP	
INFLAMMATORY CONDITIONS	RINVOQ	TB24	UPADACITINIB TAB ER 24HR	
INFLAMMATORY CONDITIONS	SILIQ	SOSY	BRODALUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	SIMPONI	SOAJ	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	SIMPONI	SOSY	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	SIMPONI ARIA	SOLN	GOLIMUMAB IV SOLN	
INFLAMMATORY CONDITIONS	SKYRIZI	PSKT	RISANKIZUMAB-RZAA SOL PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	STELARA	SOLN	USTEKINUMAB IV SOLN (FOR IV INFUSION)	
INFLAMMATORY CONDITIONS	STELARA	SOSY	USTEKINUMAB SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	TALTZ	SOAJ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR	
INFLAMMATORY CONDITIONS	TALTZ	SOSY	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	TREMFYA	SOPN	GUSELKUMAB SOLN PEN-INJECTOR	
INFLAMMATORY CONDITIONS	TREMFYA	SOSY	GUSELKUMAB SOLN PREFILLED SYRINGE	
INFLAMMATORY CONDITIONS	XELJANZ	SOLN	TOFACITINIB CITRATE ORAL SOLN	
INFLAMMATORY CONDITIONS	XELJANZ	TABS	TOFACITINIB CITRATE TAB	
INFLAMMATORY CONDITIONS	XELJANZ XR	TB24	TOFACITINIB CITRATE TAB ER 24HR	
METABOLIC BONE DISEASE	RECLAST	SOLN	ZOLEDRONIC ACID IV SOLN	
METABOLIC BONE DISEASE	ZOLEDRONIC	CONC	ZOLEDRONIC ACID INJ CONC FOR IV INFUSION	
METABOLIC BONE DISEASE	ZOLEDRONIC	SOLN	ZOLEDRONIC ACID IV SOLN	
METABOLIC BONE DISEASE	ZOLEDRONIC	SOLR	ZOLEDRONIC ACID FOR IV SOLN	
METABOLIC BONE DISEASE	ZOMETA	CONC	ZOLEDRONIC ACID INJ CONC FOR IV INFUSION	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
METABOLIC BONE DISEASE	ZOMETA	SOLN	ZOLEDRONIC ACID IV SOLN	
METABOLIC BONE DISEASE	ZOMETA	SOLR	ZOLEDRONIC ACID FOR IV SOLN	
MULTIPLE SCLEROSIS	AMPYRA	TB12	DALFAMPRIDINE TAB ER 12HR	
MULTIPLE SCLEROSIS	AUBAGIO	TABS	TERIFLUNOMIDE TAB	
MULTIPLE SCLEROSIS	AVONEX	KIT	INTERFERON BETA-1A FOR IM INJ KIT	
MULTIPLE SCLEROSIS	AVONEX PEN	AJKT	INTERFERON BETA-1A IM AUTO-INJECTOR KIT	
MULTIPLE SCLEROSIS	AVONEX PREFL	PSKT	INTERFERON BETA-1A IM PREFILLED SYRINGE KIT	
MULTIPLE SCLEROSIS	BAFIERTAM	CPDR	MONOMETHYL FUMARATE CAPSULE DELAYED RELEASE	
MULTIPLE SCLEROSIS	BETASERON	KIT	INTERFERON BETA-1B FOR INJ KIT	
MULTIPLE SCLEROSIS	BETASERON	SOLR	INTERFERON BETA-1B FOR INJ	
MULTIPLE SCLEROSIS	COPAXONE	KIT	GLATIRAMER ACETATE INJ KIT	
MULTIPLE SCLEROSIS	COPAXONE	SOSY	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE	
MULTIPLE SCLEROSIS	DALFAMPRIDIN	TB12	DALFAMPRIDINE TAB ER 12HR	
MULTIPLE SCLEROSIS	DIMETHYL FUM	CPDR	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE	
MULTIPLE SCLEROSIS	DIMETHYL FUM	MISC	DIMETHYL FUMARATE CAPSULE DR STARTER PACK	
MULTIPLE SCLEROSIS	EXTAVIA	KIT	INTERFERON BETA-1B FOR INJ KIT	X
MULTIPLE SCLEROSIS	GILENYA	CAPS	FINGOLIMOD HCL CAP	
MULTIPLE SCLEROSIS	GLATIRAMER	SOSY	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE	
MULTIPLE SCLEROSIS	GLATOPA	SOSY	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE	
MULTIPLE SCLEROSIS	KESIMPTA	SOAJ	OFATUMUMAB SOLN AUTO-INJECTOR	
MULTIPLE SCLEROSIS	MAVENCLAD	TBPK	CLADRIBINE TAB THERAPY PACK	
MULTIPLE SCLEROSIS	MAYZENT	TABS	SIPONIMOD FUMARATE TAB	
MULTIPLE SCLEROSIS	MAYZENT	TBPK	SIPONIMOD FUMARATE TAB STARTER PACK	
MULTIPLE SCLEROSIS	OCREVUS	SOLN	OCRELIZUMAB SOLN FOR IV INFUSION	
MULTIPLE SCLEROSIS	PLEGRIDY	SOPN	PEGINTERFERON BETA-1A SOLN PEN-INJECTOR	X
MULTIPLE SCLEROSIS	PLEGRIDY	SOSY	PEGINTERFERON BETA-1A SOLN PREFILLED SYRINGE	X
MULTIPLE SCLEROSIS	PLEGRIDY PEN	SOPN	PEGINTERFERON BETA-1A SOLN PEN-INJ PACK	X
MULTIPLE SCLEROSIS	PONVORY	TABS	PONESIMOD TAB	
MULTIPLE SCLEROSIS	PONVORY	TBPK	PONESIMOD TAB STARTER PACK	
MULTIPLE SCLEROSIS	REBIF	SOLN	INTERFERON BETA-1A INJ	X
MULTIPLE SCLEROSIS	REBIF	SOSY	INTERFERON BETA-1A SOLN PREF SYR	X
MULTIPLE SCLEROSIS	REBIF REBIDO	SOAJ	INTERFERON BETA-1A SOLN AUTO-INJ	X
MULTIPLE SCLEROSIS	REBIF TITRTN	SOSY	INTERFERON BETA-1A PREF SYR	X
MULTIPLE SCLEROSIS	TECFIDERA	CPDR	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE	X

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
MULTIPLE SCLEROSIS	TECFIDERA	MISC	DIMETHYL FUMARATE CAPSULE DR STARTER PACK	X
MULTIPLE SCLEROSIS	TYSABRI	CONC	NATALIZUMAB FOR IV INJ CONC	
MULTIPLE SCLEROSIS	VUMERITY	CPDR	DIROXIMEL FUMARATE CAPSULE DR STARTER BOTTLE	
MULTIPLE SCLEROSIS	ZEPOSIA	CAPS	OZANIMOD HCL CAP	
MULTIPLE SCLEROSIS	ZEPOSIA	CPPK	OZANIMOD CAP PACK	
MULTIPLE SCLEROSIS	ZEPOSIA 7DAY	CPPK	OZANIMOD CAP PACK	
MULTIPLE SCLEROSIS	ZINBRYTA	SOSY	DACLIZUMAB SOLN PREFILLED SYRINGE	
MUSCULOSKELETAL AGENTS	BOTOX COSMET	SOLR	ONABOTULINUMTOXINA (COSMETIC) FOR INJ	
NEUROLOGICAL AGENTS	BOTOX	SOLR	ONABOTULINUMTOXINA FOR INJ	
NEUROLOGICAL AGENTS	DYSPOBT	SOLR	ABOBOTULINUMTOXINA FOR IM INJ	
NEUROLOGICAL AGENTS	MYOBLOC	SOLN	RIMABOTULINUMTOXINB IM INJ	
NEUROLOGICAL AGENTS	XEOMIN	SOLR	INCOBOTULINUMTOXINA FOR IM INJ	
NEUTROPENIA	FULPHILA	SOSY	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE	X
NEUTROPENIA	GRANIX	SOLN	TBO-FILGRASTIM SUBCUTANEOUS INJ	X
NEUTROPENIA	GRANIX	SOSY	TBO-FILGRASTIM SOLN PREFILLED SYRINGE	X
NEUTROPENIA	LEUKINE	SOLN	SARGRAMOSTIM INJ	
NEUTROPENIA	LEUKINE	SOLR	SARGRAMOSTIM LYOPHILIZED FOR INJ	
NEUTROPENIA	NEULASTA	PSKT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT	
NEUTROPENIA	NEULASTA	SOSY	PEGFILGRASTIM SOLN PREFILLED SYRINGE	
NEUTROPENIA	NEUPOGEN	SOLN	FILGRASTIM INJ	X
NEUTROPENIA	NEUPOGEN	SOSY	FILGRASTIM SOLN PREFILLED SYRINGE	X
NEUTROPENIA	NIVESTYM	SOLN	FILGRASTIM-AAFI INJ	
NEUTROPENIA	NIVESTYM	SOSY	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE	
NEUTROPENIA	NYVEPRIA	SOSY	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE	
NEUTROPENIA	PROKINE	SOLR	SARGRAMOSTIM LYOPHILIZED FOR INJ	
NEUTROPENIA	UDENYCA	SOSY	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE	X
NEUTROPENIA	ZARXIO	SOSY	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE	
NEUTROPENIA	ZIEXTENZO	SOSY	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE	
ONCOLOGY - INJECTABLE	ABRAXANE	SUSR	PACLITAXEL PROTEIN-BOUND PARTICLES FOR IV SUSP	
ONCOLOGY - INJECTABLE	ADCETRIS	SOLR	BRENTUXIMAB VEDOTIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	ADRIAMYC	SOLR	DOXORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	ADRIAMYC PFS	SOLN	DOXORUBICIN HCL INJ	
ONCOLOGY - INJECTABLE	ADRIAMYC RDF	SOLR	DOXORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	ADRIAMYCIN	SOLN	DOXORUBICIN HCL INJ	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	ADRIAMYCIN	SOLR	DOXORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	ADRUCIL	SOLN	FLUOROURACIL IV SOLN 500 MG/10ML	
ONCOLOGY - INJECTABLE	ALFERON N	SOLN	INTERFERON ALFA-N3 INJ	
ONCOLOGY - INJECTABLE	ALIMTA	SOLR	PEMETREXED DISODIUM FOR IV SOLN	
ONCOLOGY - INJECTABLE	ALKERAN	SOLR	MELPHALAN HCL FOR INJ	
ONCOLOGY - INJECTABLE	AREZIA	SOLR	PAMIDRONATE DISODIUM FOR INJ	
ONCOLOGY - INJECTABLE	ARRANON	SOLN	NELARABINE IV SOLN	
ONCOLOGY - INJECTABLE	ARSENIC TRIO	SOLN	ARSENIC TRIOXIDE IV SOLN	
ONCOLOGY - INJECTABLE	ARZERRA	CONC	OFATUMUMAB CONC FOR IV INFUSION	
ONCOLOGY - INJECTABLE	ASPARLAS	SOLN	CALASPARGASE PEGOL-MKNL IV SOLN	
ONCOLOGY - INJECTABLE	AVASTIN	SOLN	BEVACIZUMAB IV SOLN (FOR INFUSION)	
ONCOLOGY - INJECTABLE	AZACITIDINE	SUSR	AZACITIDINE FOR INJ	
ONCOLOGY - INJECTABLE	BELRAPZO	SOLN	BENDAMUSTINE HCL IV SOLN	X
ONCOLOGY - INJECTABLE	BENDAMUSTINE	SOLN	BENDAMUSTINE HCL IV SOLN	X
ONCOLOGY - INJECTABLE	BENDEKA	SOLN	BENDAMUSTINE HCL IV SOLN	
ONCOLOGY - INJECTABLE	BESPOUSA	SOLR	INOTUZUMAB OZOGAMICIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	BICNU	SOLR	CARMUSTINE FOR INJ	
ONCOLOGY - INJECTABLE	BLENOXANE	SOLR	BLEOMYCIN SULFATE FOR INJ	
ONCOLOGY - INJECTABLE	BLEO 15K	SOLR	BLEOMYCIN SULF FOR INJ	
ONCOLOGY - INJECTABLE	BLEOMYCIN	SOLR	BLEOMYCIN SULFATE FOR INJ	
ONCOLOGY - INJECTABLE	BLINCYTO	SOLR	BLINATUMOMAB FOR IV INFUSION	
ONCOLOGY - INJECTABLE	BORTEZOMIB	SOLR	BORTEZOMIB FOR IV INJ	
ONCOLOGY - INJECTABLE	BUSULFAN	SOLN	BUSULFAN INJ	
ONCOLOGY - INJECTABLE	BUSULFEX	SOLN	BUSULFAN INJ	
ONCOLOGY - INJECTABLE	CAMPTOSAR	SOLN	IRINOTECAN HCL INJ	
ONCOLOGY - INJECTABLE	CARBOPLATIN	SOLN	CARBOPLATIN IV SOLN	
ONCOLOGY - INJECTABLE	CARBOPLATIN	SOLR	CARBOPLATIN IV FOR INJ	
ONCOLOGY - INJECTABLE	CARMUSTINE	SOLR	CARMUSTINE FOR INJ	
ONCOLOGY - INJECTABLE	CERUBIDINE	SOLR	DAUNORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	CISPLATIN	SOLN	CISPLATIN INJ	
ONCOLOGY - INJECTABLE	CISPLATIN	SOLR	CISPLATIN IV FOR INJ	
ONCOLOGY - INJECTABLE	CLADRIBINE	SOLN	CLADRIBINE IV SOLN	
ONCOLOGY - INJECTABLE	CLOFARABINE	SOLN	CLOFARABINE IV SOLN	
ONCOLOGY - INJECTABLE	CLOLAR	SOLN	CLOFARABINE IV SOLN	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	COSMEGEN	SOLR	DACTINOMYCIN FOR INJ	
ONCOLOGY - INJECTABLE	CYCLOPHOSPH	SOLN	CYCLOPHOSPHAMIDE IV SOLN	
ONCOLOGY - INJECTABLE	CYCLOPHOSPH	SOLR	CYCLOPHOSPHAMIDE FOR INJ	
ONCOLOGY - INJECTABLE	CYCLOPHOSPHA	SOLN	CYCLOPHOSPHAMIDE IV SOLN	
ONCOLOGY - INJECTABLE	CYRAMZA	SOLN	RAMUCIRUMAB IV SOLN (FOR INFUSION)	
ONCOLOGY - INJECTABLE	CYTARABINE	SOLN	CYTARABINE INJ	
ONCOLOGY - INJECTABLE	CYTARABINE	SOLR	CYTARABINE FOR INJ	
ONCOLOGY - INJECTABLE	CYTOSAR-U	SOLR	CYTARABINE FOR INJ	
ONCOLOGY - INJECTABLE	CYTOXAN	SOLR	CYCLOPHOSPHAMIDE FOR INJ	
ONCOLOGY - INJECTABLE	DACARBAZINE	SOLR	DACARBAZINE FOR INJ	
ONCOLOGY - INJECTABLE	DACOGEN	SOLR	DECITABINE FOR INJ	
ONCOLOGY - INJECTABLE	DACTINOMYCIN	SOLR	DACTINOMYCIN FOR INJ	
ONCOLOGY - INJECTABLE	DARZALEX	SOLN	DARATUMUMAB IV SOLN	
ONCOLOGY - INJECTABLE	DAUNORUBICIN	INJ	DAUNORUBICIN HCL INJ	
ONCOLOGY - INJECTABLE	DAUNORUBICIN	SOLN	DAUNORUBICIN HCL IV SOLN	
ONCOLOGY - INJECTABLE	DAUNORUBICIN	SOLR	DAUNORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	DAUNOXOME	INJ	DAUNORUBICIN CITRATE LIPOSOME INJ	
ONCOLOGY - INJECTABLE	DECITABINE	SOLR	DECITABINE FOR INJ	
ONCOLOGY - INJECTABLE	DEPOCYT	SUSP	CYTARABINE LIPOSOME INJ	
ONCOLOGY - INJECTABLE	DEXRAZOXANE	SOLR	DEXRAZOXANE FOR INJ	
ONCOLOGY - INJECTABLE	DOCETAXEL	CONC	DOCETAXEL FOR INJ CONC	
ONCOLOGY - INJECTABLE	DOCETAXEL	SOLN	DOCETAXEL SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	DOXIL	INJ	DOXORUBICIN HCL LIPOSOMAL INJ (FOR IV INFUSION)	
ONCOLOGY - INJECTABLE	DOXORUBICIN	INJ	DOXORUBICIN HCL LIPOSOMAL INJ (FOR IV INFUSION)	
ONCOLOGY - INJECTABLE	DOXORUBICIN	SOLN	DOXORUBICIN HCL INJ	
ONCOLOGY - INJECTABLE	DOXORUBICIN	SOLR	DOXORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	DTIC-DOME	SOLR	DACARBAZINE FOR INJ	
ONCOLOGY - INJECTABLE	ELIGARD	KIT	LEUPROLIDE ACETATE FOR SUBCUTANEOUS INJ KIT	
ONCOLOGY - INJECTABLE	ELLENC	SOLN	EPIRUBICIN HCL IV SOLN	
ONCOLOGY - INJECTABLE	ELOXATIN	SOLN	OXALIPLATIN IV SOLN	
ONCOLOGY - INJECTABLE	ELOXATIN	SOLR	OXALIPLATIN FOR IV INJ	
ONCOLOGY - INJECTABLE	ELSPAR	SOLR	ASPARAGINASE FOR INJ	
ONCOLOGY - INJECTABLE	ELZONRIS	SOLN	TAGRAXOFUSP-ERZS IV SOLN	
ONCOLOGY - INJECTABLE	EMPLICITI	SOLR	ELOTUZUMAB FOR IV SOLN	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	ENHERTU	SOLR	FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR IV SOLN	
ONCOLOGY - INJECTABLE	EPIRUBICIN	SOLN	EPIRUBICIN HCL INJ	
ONCOLOGY - INJECTABLE	EPIRUBICIN	SOLR	EPIRUBICIN HCL FOR IV INJ	
ONCOLOGY - INJECTABLE	ERBITUX	SOLN	CETUXIMAB IV SOLN	
ONCOLOGY - INJECTABLE	ETOPOPHOS	SOLR	ETOPOSIDE PHOSPHATE IV FOR INJ	
ONCOLOGY - INJECTABLE	ETOPOSIDE	SOLN	ETOPOSIDE INJ	
ONCOLOGY - INJECTABLE	EVOMELA	SOLR	MELPHALAN HCL FOR INJ (PROPYLENE GLYCOL (PG) FREE)	
ONCOLOGY - INJECTABLE	FASLODEX	SOLN	FULVESTRANT INJ	
ONCOLOGY - INJECTABLE	FLOXURIDINE	SOLR	FLOXURIDINE FOR INJ	
ONCOLOGY - INJECTABLE	FLUDARA	SOLR	FLUDARABINE PHOSPHATE FOR INJ	
ONCOLOGY - INJECTABLE	FLUDARABINE	SOLN	FLUDARABINE PHOSPHATE INJ	
ONCOLOGY - INJECTABLE	FLUDARABINE	SOLR	FLUDARABINE PHOSPHATE FOR INJ	
ONCOLOGY - INJECTABLE	FOLOTYN	SOLN	PRALATREXATE IV INJ	
ONCOLOGY - INJECTABLE	FUDR	SOLR	FLOXURIDINE FOR INJ	
ONCOLOGY - INJECTABLE	FULVESTRANT	SOLN	FULVESTRANT INJ	
ONCOLOGY - INJECTABLE	FUSILEV	SOLR	LEVOLEUCOVORIN CALCIUM FOR IV INJ	
ONCOLOGY - INJECTABLE	GAZYVA	SOLN	OBINUTUZUMAB SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	GEMCITABINE	SOLN	GEMCITABINE HCL INJ	
ONCOLOGY - INJECTABLE	GEMCITABINE	SOLR	GEMCITABINE HCL FOR INJ	
ONCOLOGY - INJECTABLE	GEMZAR	SOLR	GEMCITABINE HCL FOR INJ	
ONCOLOGY - INJECTABLE	HALAVEN	SOLN	ERIBULIN MESYLATE INJ	
ONCOLOGY - INJECTABLE	HERCEP HYLEC	SOLN	TRASTUZUMAB-HYALURONIDASE-OYSK INJ	
ONCOLOGY - INJECTABLE	HERCEPTIN	SOLR	TRASTUZUMAB FOR IV SOLN	
ONCOLOGY - INJECTABLE	HERZUMA	SOLR	TRASTUZUMAB-PKRB FOR IV SOLN	X
ONCOLOGY - INJECTABLE	HYCAMTIN	SOLR	TOPOTECAN HCL FOR INJ	
ONCOLOGY - INJECTABLE	IDAMYCIN PFS	SOLN	IDARUBICIN HCL IV INJ	
ONCOLOGY - INJECTABLE	IDARUBICIN	SOLN	IDARUBICIN HCL IV INJ	
ONCOLOGY - INJECTABLE	IFEX	SOLR	IFOSFAMIDE FOR INJ	
ONCOLOGY - INJECTABLE	IFEX/MESNEX	KIT	IFOSFAMIDE & MESNA INJ KIT	
ONCOLOGY - INJECTABLE	IFOSFAMIDE	KIT	IFOSFAMIDE & MESNA INJ KIT	
ONCOLOGY - INJECTABLE	IFOSFAMIDE	SOLN	IFOSFAMIDE IV INJ	
ONCOLOGY - INJECTABLE	IFOSFAMIDE	SOLR	IFOSFAMIDE FOR INJ	
ONCOLOGY - INJECTABLE	INFUGEM	SOLN	GEMCITABINE HCL-NACL IV SOLN	
ONCOLOGY - INJECTABLE	INTRON A	SOLN	INTERFERON ALFA-2B INJ	



Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	INTRON A	SOLR	INTERFERON ALFA-2B FOR INJ	
ONCOLOGY - INJECTABLE	INTRON-A	KIT	INTERFERON ALFA-2B INJ KIT	
ONCOLOGY - INJECTABLE	INTRON-A	SOLN	INTERFERON ALFA-2B INJ	
ONCOLOGY - INJECTABLE	INTRON-A	SOLR	INTERFERON ALFA-2B FOR INJ	
ONCOLOGY - INJECTABLE	IRINOTECAN	SOLN	IRINOTECAN HCL INJ	
ONCOLOGY - INJECTABLE	ISTODAX	SOLR	ROMIDEPSIN FOR IV INJ	
ONCOLOGY - INJECTABLE	ISTODAX OVR	SOLR	ROMIDEPSIN FOR IV INJ	
ONCOLOGY - INJECTABLE	IXEMPRA KIT	SOLR	IXABEPILONE FOR IV INFUSION	
ONCOLOGY - INJECTABLE	JELMYTO	SOLR	MITOMYCIN FOR PYELOALYCEAL SOLN	
ONCOLOGY - INJECTABLE	JEVTANA	SOLN	CABAZITAXEL INJ (FOR IV INFUSION)	
ONCOLOGY - INJECTABLE	KADCYLA	SOLR	ADO-TRASTUZUMAB EMTANSINE FOR IV SOLN	
ONCOLOGY - INJECTABLE	KANJINTI	SOLR	TRASTUZUMAB-ANNS FOR IV SOLN	
ONCOLOGY - INJECTABLE	KEPIVANCE	SOLR	PALIFERMIN FOR IV INJ	
ONCOLOGY - INJECTABLE	KEYTRUDA	SOLN	PEMBROLIZUMAB IV SOLN	
ONCOLOGY - INJECTABLE	KEYTRUDA	SOLR	PEMBROLIZUMAB FOR IV SOLN	
ONCOLOGY - INJECTABLE	KHAPZORY	SOLR	LEVOLEUCOVORIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	KYPROLIS	SOLR	CARFILZOMIB FOR INJ	
ONCOLOGY - INJECTABLE	LEUPROLIDE	KIT	LEUPROLIDE ACETATE INJ KIT	
ONCOLOGY - INJECTABLE	LEUPROLIDE	SOLN	LEUPROLIDE ACETATE INJ	
ONCOLOGY - INJECTABLE	LEUSTATIN	SOLN	CLADRIBINE INJ	
ONCOLOGY - INJECTABLE	LEVOLEUCOVOR	SOLR	LEVOLEUCOVORIN CALCIUM FOR IV INJ	
ONCOLOGY - INJECTABLE	LIPODOX	INJ	DOXORUBICIN HCL LIPOSOMAL INJ (FOR IV INFUSION)	
ONCOLOGY - INJECTABLE	LIPODOX 50	INJ	DOXORUBICIN HCL LIPOSOMAL INJ (FOR IV INFUSION)	
ONCOLOGY - INJECTABLE	LUPR DEP-PED	KIT	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT	
ONCOLOGY - INJECTABLE	LUPRON	KIT	LEUPROLIDE ACETATE INJ KIT	
ONCOLOGY - INJECTABLE	LUPRON	SOLN	LEUPROLIDE ACETATE INJ	
ONCOLOGY - INJECTABLE	LUPRON 6-PK	SOLN	LEUPROLIDE ACETATE INJ	
ONCOLOGY - INJECTABLE	LUPRON DEPOT	KIT	LEUPROLIDE ACETATE FOR INJ KIT	
ONCOLOGY - INJECTABLE	MELPHALAN	SOLR	MELPHALAN HCL FOR INJ	
ONCOLOGY - INJECTABLE	MESNA	SOLN	MESNA INJ	
ONCOLOGY - INJECTABLE	MESNEX	SOLN	MESNA INJ	
ONCOLOGY - INJECTABLE	MITOMYCIN	SOLR	MITOMYCIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	MITOMYCIN	SOSY	MITOMYCIN SOLN FOR INTRAVESICAL INSTILLATION	
ONCOLOGY - INJECTABLE	MITOXANTRON	CONC	MITOXANTRONE HCL INJ CONC	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	MUSTARGEN	SOLR	MECHLORETHAMINE HCL FOR INJ	
ONCOLOGY - INJECTABLE	MUTAMYCIN	SOLR	MITOMYCIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	MVASI	SOLN	BEVACIZUMAB-AWWB IV SOLN (FOR INFUSION)	
ONCOLOGY - INJECTABLE	MYLOTARG	SOLR	GEMTUZUMAB OZOGAMICIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	NAVELBINE	SOLN	VINORELBINE TARTRATE INJ	
ONCOLOGY - INJECTABLE	NEOSAR	SOLR	CYCLOPHOSPHAMIDE FOR INJ	
ONCOLOGY - INJECTABLE	NIPENT	SOLR	PENTOSTATIN FOR INJ	
ONCOLOGY - INJECTABLE	NOVANTRONE	CONC	MITOXANTRONE HCL INJ CONC	
ONCOLOGY - INJECTABLE	OGIVRI	SOLR	TRASTUZUMAB-DKST FOR IV SOLN	X
ONCOLOGY - INJECTABLE	ONCASPAR	SOLN	PEGASPARGASE INJ	
ONCOLOGY - INJECTABLE	ONCOVIN	SOLN	VINCRISTINE SULFATE IV SOLN	
ONCOLOGY - INJECTABLE	ONIVYDE	INJ	IRINOTECAN HCL LIPOSOME IV INJ	
ONCOLOGY - INJECTABLE	ONTAK	SOLN	DENILEUKIN DIFTITOX IV SOLN	
ONCOLOGY - INJECTABLE	ONTRUZANT	SOLR	TRASTUZUMAB-DTTB FOR IV SOLN	X
ONCOLOGY - INJECTABLE	ONXOL	CONC	PACLITAXEL IV CONC	
ONCOLOGY - INJECTABLE	OPDIVO	SOLN	NIVOLUMAB IV SOLN	
ONCOLOGY - INJECTABLE	OXALIPLATIN	SOLN	OXALIPLATIN IV SOLN	
ONCOLOGY - INJECTABLE	OXALIPLATIN	SOLR	OXALIPLATIN FOR IV INJ	
ONCOLOGY - INJECTABLE	PACLITAXEL	CONC	PACLITAXEL IV CONC	
ONCOLOGY - INJECTABLE	PADCEV	SOLR	ENFORTUMAB VEDOTIN-EJFV FOR IV SOLN	
ONCOLOGY - INJECTABLE	PAMIDRONATE	SOLN	PAMIDRONATE DISODIUM IV SOLN	
ONCOLOGY - INJECTABLE	PAMIDRONATE	SOLR	PAMIDRONATE DISODIUM FOR INJ	
ONCOLOGY - INJECTABLE	PARAPLATIN	SOLN	CARBOPLATIN IV SOLN	
ONCOLOGY - INJECTABLE	PARAPLATIN	SOLR	CARBOPLATIN IV FOR INJ	
ONCOLOGY - INJECTABLE	PENTOSTATIN	SOLR	PENTOSTATIN FOR INJ	
ONCOLOGY - INJECTABLE	PERJETA	SOLN	PERTUZUMAB SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	PHESGO	SOLN	PERTUZUMAB-TRASTUZ-HYALURON-ZZXF INJ	
ONCOLOGY - INJECTABLE	PLATINOL	SOLR	CISPLATIN IV FOR INJ	
ONCOLOGY - INJECTABLE	PLATINOL AQ	SOLN	CISPLATIN INJ	
ONCOLOGY - INJECTABLE	POLIVY	SOLR	POLATUZUMAB VEDOTIN-PIIQ FOR IV SOLUTION	
ONCOLOGY - INJECTABLE	PORTRAZZA	SOLN	NECITUMUMAB IV SOLN	
ONCOLOGY - INJECTABLE	PROLEUKIN	SOLR	ALDESLEUKIN FOR IV SOLN	
ONCOLOGY - INJECTABLE	RIABNI	SOLN	RITUXIMAB-ARRX IV SOLN	
ONCOLOGY - INJECTABLE	RITUXAN	SOLN	RITUXIMAB IV SOLN	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	ROMIDEPSIN	SOLN	ROMIDEPSIN IV SOLN	
ONCOLOGY - INJECTABLE	ROMIDEPSIN	SOLR	ROMIDEPSIN FOR IV INJ	
ONCOLOGY - INJECTABLE	RUBEX	SOLR	DOXORUBICIN HCL FOR INJ	
ONCOLOGY - INJECTABLE	RUXIENCE	SOLN	RITUXIMAB-PVVR IV SOLN	
ONCOLOGY - INJECTABLE	SYLATRON	KIT	PEGINTERFERON ALFA-2B FOR INJ KIT	
ONCOLOGY - INJECTABLE	SYLVANT	SOLR	SILTUXIMAB FOR IV INFUSION	
ONCOLOGY - INJECTABLE	SYNRIBO	SOLR	OMACETAXINE MEPESUCCINATE FOR INJ	
ONCOLOGY - INJECTABLE	TARABINE PFS	SOLR	CYTARABINE FOR INJ	
ONCOLOGY - INJECTABLE	TAXOL	CONC	PACLITAXEL IV CONC	
ONCOLOGY - INJECTABLE	TAXOTERE	CONC	DOCETAXEL FOR INJ CONC	
ONCOLOGY - INJECTABLE	TECENTRIQ	SOLN	ATEZOLIZUMAB IV SOLN	
ONCOLOGY - INJECTABLE	TEMODAR	SOLR	TEMOZOLOMIDE FOR IV SOLN	
ONCOLOGY - INJECTABLE	TEMSIROLIMUS	SOLN	TEMSIROLIMUS SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	TENIPOSIDE	SOLN	TENIPOSIDE IV SOLN	
ONCOLOGY - INJECTABLE	TEPADINA	SOLR	THIOTEPA FOR INJ	
ONCOLOGY - INJECTABLE	THERACYS	SUSR	BCG LIVE INTRAVESICAL FOR SUSP	
ONCOLOGY - INJECTABLE	THIOPLEX	SOLR	THIOTEPA FOR INJ	
ONCOLOGY - INJECTABLE	THIOTEPA	SOLR	THIOTEPA FOR INJ	
ONCOLOGY - INJECTABLE	TICE BCG	SUSR	BCG LIVE INTRAVESICAL FOR SUSP	
ONCOLOGY - INJECTABLE	TOPOSAR	SOLN	ETOPOSIDE INJ	
ONCOLOGY - INJECTABLE	TOPOTECAN	SOLN	TOPOTECAN HCL INJ	
ONCOLOGY - INJECTABLE	TOPOTECAN	SOLR	TOPOTECAN HCL FOR INJ	
ONCOLOGY - INJECTABLE	TORISEL	SOLN	TEMSIROLIMUS SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	TOTECT	SOLR	DEXRAZOXANE FOR INJ	
ONCOLOGY - INJECTABLE	TRAZIMERA	SOLR	TRASTUZUMAB-QYYP FOR IV SOLN	
ONCOLOGY - INJECTABLE	TREANDA	SOLR	BENDAMUSTINE HCL FOR IV SOLN	X
ONCOLOGY - INJECTABLE	TRELSTAR	SUSR	TRIPTORELIN PAMOATE FOR IM SUSP	
ONCOLOGY - INJECTABLE	TRELSTAR DEP	SUSR	TRIPTORELIN PAMOATE FOR IM SUSP	
ONCOLOGY - INJECTABLE	TRELSTAR LA	SUSR	TRIPTORELIN PAMOATE FOR IM SUSP	
ONCOLOGY - INJECTABLE	TRELSTAR MIX	SUSR	TRIPTORELIN PAMOATE FOR IM SUSP	
ONCOLOGY - INJECTABLE	TRISENOX	SOLN	ARSENIC TRIOXIDE IV SOLN	
ONCOLOGY - INJECTABLE	TRUXIMA	SOLN	RITUXIMAB-ABBS IV SOLN	X
ONCOLOGY - INJECTABLE	VALRUBICIN	SOLN	VALRUBICIN SOLN FOR INTRAVESICAL INSTILLATION	
ONCOLOGY - INJECTABLE	VALSTAR	SOLN	VALRUBICIN SOLN FOR INTRAVESICAL INSTILLATION	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - INJECTABLE	VANTAS	KIT	HISTRELIN ACETATE IMPLANT KIT	
ONCOLOGY - INJECTABLE	VECTIBIX	SOLN	PANITUMUMAB IV SOLN	
ONCOLOGY - INJECTABLE	VELBAN	SOLR	VINBLASTINE SULFATE FOR INJ	
ONCOLOGY - INJECTABLE	VELCADE	SOLR	BORTEZOMIB FOR INJ	
ONCOLOGY - INJECTABLE	VELSAR	SOLR	VINBLASTINE SULFATE FOR INJ	
ONCOLOGY - INJECTABLE	VEPESID	SOLN	ETOPOSIDE INJ	
ONCOLOGY - INJECTABLE	VIDAZA	SUSR	AZACITIDINE FOR INJ	
ONCOLOGY - INJECTABLE	VINBLASTINE	SOLN	VINBLASTINE SULFATE INJ	
ONCOLOGY - INJECTABLE	VINBLASTINE	SOLR	VINBLASTINE SULFATE FOR INJ	
ONCOLOGY - INJECTABLE	VINCASAR PFS	SOLN	VINCRISTINE SULFATE IV SOLN	
ONCOLOGY - INJECTABLE	VINCRISTINE	SOLN	VINCRISTINE SULFATE IV SOLN	
ONCOLOGY - INJECTABLE	VINORELBINE	SOLN	VINORELBINE TARTRATE INJ	
ONCOLOGY - INJECTABLE	VUMON	SOLN	TENIPOSIDE IV SOLN	
ONCOLOGY - INJECTABLE	XGEVA	SOLN	DENOSUMAB INJ	
ONCOLOGY - INJECTABLE	YERVOY	SOLN	IPILIMUMAB SOLN FOR IV INFUSION	
ONCOLOGY - INJECTABLE	YONDELIS	SOLR	TRABECTEDIN FOR INJ	
ONCOLOGY - INJECTABLE	ZALTRAP	SOLN	ZIV-AFLIBERCEPT IV SOLN (FOR INFUSION)	
ONCOLOGY - INJECTABLE	ZANOSAR	SOLR	STREPTOZOCIN FOR INJ	
ONCOLOGY - INJECTABLE	ZINECARD	SOLR	DEXRAZOXANE FOR INJ	
ONCOLOGY - INJECTABLE	ZIRABEV	SOLN	BEVACIZUMAB-BVZR IV SOLN (FOR INFUSION)	
ONCOLOGY - INJECTABLE	ZOLADEX	IMPL	GOSERELIN ACETATE IMPLANT	
ONCOLOGY - ORAL	ABIRATERONE	TABS	ABIRATERONE ACETATE TAB	
ONCOLOGY - ORAL	AFINITOR	TABS	EVEROLIMUS TAB	<b>2.5,5,7.5mg</b>
ONCOLOGY - ORAL	AFINITOR DIS	TBSO	EVEROLIMUS TAB FOR ORAL SUSP	
ONCOLOGY - ORAL	ALECENSA	CAPS	ALECTINIB HCL CAP (BASE EQUIVALENT)	
ONCOLOGY - ORAL	ALKERAN	TABS	MELPHALAN TAB	
ONCOLOGY - ORAL	BEXAROTENE	CAPS	BEXAROTENE CAP	
ONCOLOGY - ORAL	BOSULIF	TABS	BOSUTINIB TAB	
ONCOLOGY - ORAL	BRUKINSA	CAPS	ZANUBRUTINIB CAP	
ONCOLOGY - ORAL	CABOMETYX	TABS	CABOZANTINIB S-MALATE TAB	
ONCOLOGY - ORAL	CAPECITABINE	TABS	CAPECITABINE TAB	
ONCOLOGY - ORAL	CEENU	CAPS	LOMUSTINE CAP	
ONCOLOGY - ORAL	COMETRIQ	KIT	CABOZANTINIB S-MALATE CAP KIT	
ONCOLOGY - ORAL	COPIKTRA	CAPS	DUVELISIB CAP	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - ORAL	COTELLIC	TABS	COBIMETINIB FUMARATE TAB	
ONCOLOGY - ORAL	DAURISMO	TABS	GLASDEGIB MALEATE TAB	
ONCOLOGY - ORAL	ERIVEDGE	CAPS	VISMODEGIB CAP	
ONCOLOGY - ORAL	ERLEADA	TABS	APALUTAMIDE TAB	X
ONCOLOGY - ORAL	ERLOTINIB	TABS	ERLOTINIB HCL TAB	
ONCOLOGY - ORAL	ETOPOSIDE	CAPS	ETOPOSIDE CAP	
ONCOLOGY - ORAL	EVEROLIMUS	TABS	EVEROLIMUS TAB	
ONCOLOGY - ORAL	FARYDAK	CAPS	PANOBINOSTAT LACTATE CAP	
ONCOLOGY - ORAL	GLEEVEC	CAPS	IMATINIB MESYLATE CAP	
ONCOLOGY - ORAL	GLEEVEC	TABS	IMATINIB MESYLATE TAB	X
ONCOLOGY - ORAL	GLEOSTINE	CAPS	LOMUSTINE CAP	
ONCOLOGY - ORAL	HYCAMTIN	CAPS	TOPOTECAN HCL CAP	
ONCOLOGY - ORAL	IBRANCE	CAPS	PALBOCICLIB CAP	
ONCOLOGY - ORAL	IBRANCE	TABS	PALBOCICLIB TAB	
ONCOLOGY - ORAL	IDHIFA	TABS	ENASIDENIB MESYLATE TAB	
ONCOLOGY - ORAL	IMATINIB MES	TABS	IMATINIB MESYLATE TAB	
ONCOLOGY - ORAL	INLYTA	TABS	AXITINIB TAB	
ONCOLOGY - ORAL	INQOVI	TABS	DECITABINE-CEDAZURIDINE TAB	
ONCOLOGY - ORAL	INREBIC	CAPS	FEDRATINIB HCL CAP	
ONCOLOGY - ORAL	IRESSA	TABS	GEFITINIB TAB	
ONCOLOGY - ORAL	JAKAFI	TABS	RUXOLITINIB PHOSPHATE TAB	
ONCOLOGY - ORAL	KISQALI	TBPK	RIBOCICLIB SUCCINATE TAB PACK	
ONCOLOGY - ORAL	KISQALI 200	TBPK	RIBOCICLIB TAB & LETROZOLE TBPK	
ONCOLOGY - ORAL	KISQALI 400	TBPK	RIBOCICLIB TAB & LETROZOLE TBPK	
ONCOLOGY - ORAL	KISQALI 600	TBPK	RIBOCICLIB TAB & LETROZOLE TBPK	
ONCOLOGY - ORAL	LAPATINIB	TABS	LAPATINIB DITOSYLATE TAB	
ONCOLOGY - ORAL	LENVIMA	CPPK	LENVATINIB CAP THERAPY PACK	
ONCOLOGY - ORAL	LOMUSTINE	CAPS	LOMUSTINE CAP	
ONCOLOGY - ORAL	LONSURF	TABS	TRIFLURIDINE-TIPIRACIL TAB	
ONCOLOGY - ORAL	LORBRENA	TABS	LORLATINIB TAB	
ONCOLOGY - ORAL	LYNPARZA	CAPS	OLAPARIB CAP	
ONCOLOGY - ORAL	LYNPARZA	TABS	OLAPARIB TAB	
ONCOLOGY - ORAL	MEKINIST	TABS	TRAMETINIB DIMETHYL SULFOXIDE TAB	
ONCOLOGY - ORAL	MELPHALAN	TABS	MELPHALAN TAB	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - ORAL	MESNEX	TABS	MESNA TAB	
ONCOLOGY - ORAL	NERLYNX	TABS	NERATINIB MALEATE TAB	
ONCOLOGY - ORAL	NEXAVAR	TABS	SORAFENIB TOSYLATE TAB	
ONCOLOGY - ORAL	NINLARO	CAPS	IXAZOMIB CITRATE CAP	
ONCOLOGY - ORAL	NUBEQA	TABS	DAROLUTAMIDE TAB	
ONCOLOGY - ORAL	ODOMZO	CAPS	SONIDEGB PHOSPHATE CAP	
ONCOLOGY - ORAL	ONUREG	TABS	AZACITIDINE TAB	
ONCOLOGY - ORAL	PIQRAY 200MG	TBPK	ALPELISIB TAB THERAPY PACK	
ONCOLOGY - ORAL	PIQRAY 250MG	TBPK	ALPELISIB TAB PACK	
ONCOLOGY - ORAL	PIQRAY 300MG	TBPK	ALPELISIB TAB PACK	
ONCOLOGY - ORAL	POMALYST	CAPS	POMALIDOMIDE CAP	
ONCOLOGY - ORAL	RETEVMO	CAPS	SELPERCATINIB CAP	
ONCOLOGY - ORAL	REVLIMID	CAPS	LENALIDOMIDE CAPS	
ONCOLOGY - ORAL	ROZLYTREK	CAPS	ENTRECTINIB CAP	
ONCOLOGY - ORAL	RUBRACA	TABS	RUCAPARIB CAMSYLATE TAB	
ONCOLOGY - ORAL	RYDAPT	CAPS	MIDOSTAURIN CAP	
ONCOLOGY - ORAL	SPRYCEL	TABS	DASATINIB TAB	
ONCOLOGY - ORAL	STIVARGA	TABS	REGORAFENIB TAB	
ONCOLOGY - ORAL	SUTENT	CAPS	SUNITINIB MALATE CAP	
ONCOLOGY - ORAL	TABLOID	TABS	THIOGUANINE TAB	
ONCOLOGY - ORAL	TABRECTA	TABS	CAPMATINIB HCL TAB	X
ONCOLOGY - ORAL	TAFINLAR	CAPS	DABRAFENIB MESYLATE CAP	
ONCOLOGY - ORAL	TAGRISSE	TABS	OSIMERTINIB MESYLATE TAB	
ONCOLOGY - ORAL	TALZENNA	CAPS	TALAZOPARIB TOSYLATE CAP	
ONCOLOGY - ORAL	TARCEVA	TABS	ERLOTINIB HCL TAB	
ONCOLOGY - ORAL	TARGRETIN	CAPS	BEXAROTENE CAP	X
ONCOLOGY - ORAL	TASIGNA	CAPS	NILOTINIB HCL CAP	
ONCOLOGY - ORAL	TEMODAR	CAPS	TEMOZOLOMIDE CAP	
ONCOLOGY - ORAL	TEMOZOLOMIDE	CAPS	TEMOZOLOMIDE CAP	
ONCOLOGY - ORAL	THALOMID	CAPS	THALIDOMIDE CAP	
ONCOLOGY - ORAL	THIOGUANINE	TABS	THIOGUANINE TAB	
ONCOLOGY - ORAL	TIBSOVO	TABS	IVOSIDENIB TAB	
ONCOLOGY - ORAL	TRETINOIN	CAPS	TRETINOIN CAP	
ONCOLOGY - ORAL	TYKERB	TABS	LAPATINIB DITOSYLATE TAB	

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
ONCOLOGY - ORAL	VEPESID	CAPS	ETOPOSIDE CAP	
ONCOLOGY - ORAL	VERZENIO	TABS	ABEMACICLIB TAB	
ONCOLOGY - ORAL	VESANOID	CAPS	TRETINOIN CAP	
ONCOLOGY - ORAL	VIZIMPRO	TABS	DACOMITINIB TAB	
ONCOLOGY - ORAL	VOTRIENT	TABS	PAZOPANIB HCL TAB	
ONCOLOGY - ORAL	XALKORI	CAPS	CRIZOTINIB CAP	
ONCOLOGY - ORAL	XELODA	TABS	CAPECITABINE TAB	
ONCOLOGY - ORAL	XTANDI	CAPS	ENZALUTAMIDE CAP	
ONCOLOGY - ORAL	XTANDI	TABS	ENZALUTAMIDE TAB	
ONCOLOGY - ORAL	YONSA	TABS	ABIRATERONE ACETATE TAB	X
ONCOLOGY - ORAL	ZEJULA	CAPS	NIRAPARIB TOSYLATE CAP	
ONCOLOGY - ORAL	ZELBORAF	TABS	VEMURAFENIB TAB	
ONCOLOGY - ORAL	ZOLINZA	CAPS	VORINOSTAT CAP	
ONCOLOGY - ORAL	ZYDELIG	TABS	IDELALISIB TAB	
ONCOLOGY - ORAL	ZYKADIA	CAPS	CERITINIB CAP	
ONCOLOGY - ORAL	ZYKADIA	TABS	CERITINIB TAB	
ONCOLOGY - ORAL	ZYTIGA	TABS	ABIRATERONE ACETATE TAB	X
ONCOLOGY - TOPICAL	TARGRETIN	GEL	BEXAROTENE GEL 1%	
ONCOLOGY - TOPICAL	VALCHLOR	GEL	MECHLORETHAMINE HCL GEL	
OPHTHALMIC AGENTS	BEOVU	SOLN	BROLUCIZUMAB-DBLL INTRAVITREAL SOLN	X
OPHTHALMIC AGENTS	EYLEA	SOLN	AFLIBERCEPT INTRAVITREAL INJ	
OPHTHALMIC AGENTS	EYLEA	SOSY	AFLIBERCEPT INTRAVITREAL SOLN PREF SYR	
OPHTHALMIC AGENTS	ILUVIEN	IMPL	FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT	
OPHTHALMIC AGENTS	LUCENTIS	SOLN	RANIBIZUMAB INTRAVITREAL INJ	
OPHTHALMIC AGENTS	LUCENTIS	SOSY	RANIBIZUMAB INTRAVITREAL SOLN PREF SYR	
OPHTHALMIC AGENTS	MACUGEN	SOLN	PEGAPTANIB SODIUM INTRAVITREOUS INJ	
OPHTHALMIC AGENTS	OZURDEX	IMPL	DEXAMETHASONE INTRAVITREAL	
OPHTHALMIC AGENTS	RETISERT	IMPL	FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT	
OPHTHALMIC AGENTS	VISUDYNE	SOLR	VERTEPORFIN FOR IV SOLN	
OPHTHALMIC AGENTS	YUTIQ	IMPL	FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT	
OPIOID ANTAGONISTS	SUBLOCADE	SOSY	BUPRENORPHINE EXTENDED RELEASE SOLN PREF SYR	
OSTEOARTHRITIS	DUROLANE	PRSY	SODIUM HYALURONATE INTRA-ARTICULAR GEL PREF SYR	
OSTEOARTHRITIS	EUFLEXXA	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	
OSTEOARTHRITIS	GEL-ONE	PRSY	CROSS-LINKED HYALURONATE GEL PREFILLED SYRINGE	X

Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
OSTEOARTHRITIS	GELSYN-3	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	
OSTEOARTHRITIS	GENVISC 850	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	HYALGAN	SOLN	SODIUM HYALURONATE INTRA-ARTICULAR INJ	X
OSTEOARTHRITIS	HYALGAN	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	HYMOVIS	SOSY	HYALURONAN INTRA-ARTICULAR SOLN PREFILLED SYRINGE	X
OSTEOARTHRITIS	MONOVISC	SOSY	HYALURONAN INTRA-ARTICULAR SOLN PREFILLED SYRINGE	X
OSTEOARTHRITIS	ORTHOVISC	SOSY	HYALURONAN INTRA-ARTICULAR SOLN PREFILLED SYRINGE	X
OSTEOARTHRITIS	SODIUM HYALU	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	SUPARTZ	SOLN	SODIUM HYALURONATE INTRA-ARTICULAR INJ	X
OSTEOARTHRITIS	SUPARTZ	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	SUPARTZ FX	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	SYNVISC	INJ	HYLAN INTRA-ARTICULAR INJ	X
OSTEOARTHRITIS	SYNVISC	SOSY	HYLAN INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE	X
OSTEOARTHRITIS	SYNVISC ONE	SOSY	HYLAN INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE	X
OSTEOARTHRITIS	TRILURON	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	TRIVISC	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOARTHRITIS	VISCO-3	SOSY	SODIUM HYALURONATE INTRA-ARTICULAR SOLN PREF SYR	X
OSTEOPOROSIS	EVENITY	SOSY	ROMOSOZUMAB-AQQG INJ SOLN PREFILLED SYRINGE	
OSTEOPOROSIS	FORTEO	SOLN	TERIPARATIDE (RECOMBINANT) INJ	X
OSTEOPOROSIS	FORTEO	SOPN	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ	X
OSTEOPOROSIS	PROLIA	SOSY	DENOSUMAB INJ SOLN PREFILLED SYRINGE	
OSTEOPOROSIS	TERIPARATIDE	SOPN	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ	
OSTEOPOROSIS	TYMLOS	SOPN	ABALOPARATIDE SUBCUTANEOUS SOLN PEN-INJECTOR	
PAIN MANAGEMENT	PRIALT	SOLN	ZICONOTIDE ACETATE INTRATHECAL INJ	
PARKINSON'S DISEASE	APOKYN	SOCT	APOMORPHINE HCL SOLN CARTRIDGE	
PARKINSON'S DISEASE	APOKYN	SOLN	APOMORPHINE HYDROCHLORIDE INJ	
PARKINSON'S DISEASE	KYNMOBI	FILM	APOMORPHINE HYDROCHLORIDE FILM	
PULMONARY FIBROSIS	ESBRIET	CAPS	PIRFENIDONE CAP	
PULMONARY FIBROSIS	ESBRIET	TABS	PIRFENIDONE TAB	
PULMONARY FIBROSIS	OFEV	CAPS	NINTEDANIB ESYLATE CAP	
PULMONARY HYPERTENSION	ADCIRCA	TABS	TADALAFIL TAB (PAH)	X
PULMONARY HYPERTENSION	ALYQ	TABS	TADALAFIL TAB (PAH)	
PULMONARY HYPERTENSION	AMBRISENTAN	TABS	AMBRISENTAN TAB	
PULMONARY HYPERTENSION	BOSENTAN	TABS	BOSENTAN TAB	



Effective Date: 07/01/2021

## SPECIALTY DRUG LIST

Revised Date: 05/07/2021

DRUG CLASS	DRUG NAME	DOSAGE FORM	GENERIC NAME	EXCLUDED ON NATIONAL PERFORMANCE FORMULARY
PULMONARY HYPERTENSION	LETAIRIS	TABS	AMBRISENTAN TAB	
PULMONARY HYPERTENSION	REVATIO	SOLN	SILDENAFIL CITRATE IV SOLN	
PULMONARY HYPERTENSION	REVATIO	SUSR	SILDENAFIL CITRATE FOR SUSPENSION	
PULMONARY HYPERTENSION	REVATIO	TABS	SILDENAFIL CITRATE TAB	
PULMONARY HYPERTENSION	SILDENAFIL	SOLN	SILDENAFIL CITRATE IV SOLN	
PULMONARY HYPERTENSION	SILDENAFIL	SUSR	SILDENAFIL CITRATE FOR SUSPENSION	
PULMONARY HYPERTENSION	SILDENAFIL	TABS	SILDENAFIL CITRATE TAB	
PULMONARY HYPERTENSION	TADALAFIL	TABS	TADALAFIL TAB (PAH)	
PULMONARY HYPERTENSION	TRACLEER	TABS	BOSENTAN TAB	<b>62.5,125mg</b>
PULMONARY HYPERTENSION	TRACLEER	TBSO	BOSENTAN TAB FOR ORAL SUSP	
RSV	SYNAGIS	SOLN	PALIVIZUMAB IM SOLN	
RSV	SYNAGIS	SOLR	PALIVIZUMAB FOR INJ	
SUBSTANCE ABUSE TREATMENT	VIVITROL	SUSR	NALTREXONE FOR IM EXTENDED RELEASE SUSP	
<p><b>About this document:</b> Where differences exist between this formulary and your benefit plan documents, the benefit plan documents rule.                      This may not be a complete list of medications, and not all medications listed may be covered by your plan.</p>				
<p>All brand or product names are trademarks or registered marks of their respective owners.</p>				